O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.
11-14 September 2014
LONDON
14th EURETINA Congress
Programme
NICE
15th
EURETINA Congress
17 – 20 September 2015
LONDON14th EURETINA Congress
1CONTENTS
	 Board & Officers 2
	 Letter from the President 3
	 Programme Overview 4
	 Surgica...
LONDON14th EURETINA Congress
2
President
Francesco Bandello ITALY
Vice-President
Ursula Schmidt-Erfurth AUSTRIA
General Se...
LONDON14th EURETINA Congress
3PRESIDENT’S LETTER
EURETINA
Temple House
Temple Road
Blackrock
Co. Dublin
Ireland
Tel: + 353...
LONDON14th EURETINA Congress
4 PROGRAMME OVERVIEW
THURSDAY11SEPTEMBER
08.00
09.00
10.00
11.00
12.00
13.00
14.00
15.00
16.0...
LONDON14th EURETINA Congress
5PROGRAMME OVERVIEW
FRIDAY12SEPTEMBER
08.00
09.00
10.00
11.00
12.00
13.00
14.00
15.00
16.00
1...
LONDON14th EURETINA Congress
6 PROGRAMME OVERVIEW
SATURDAY13SEPTEMBER
08.00
09.00
10.00
11.00
12.00
13.00
14.00
15.00
16.0...
LONDON14th EURETINA Congress
7PROGRAMME OVERVIEW
SUNDAY14SEPTEMBER
08.00
09.00
10.00
11.00
12.00
13.00
14.00
15.00
16.00
1...
LONDON14th EURETINA Congress
8 SURGICAL SKILLS TRAINING COURSES
Surgical Skills Training Courses
Chairperson:	 S. Binder A...
THURSDAY11 September
LONDON
9
14th EURETINA Congress
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER10
08.00 – 16.00
104TH RETINAL DETACHMENT COURSE
Diagnostics, Options fo...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 11
14.00
10. 	 The Diabetic Eye
	 Moderators: 	 F. LaFranco USA
		 J. S...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER12
08.00 – 10.00
FREE PAPER SESSION 1
Vitreoretinal Surgery I
Venue: Aud...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 13
08.00 – 10.00
FREE PAPER SESSION 2
Vascular Diseases  Diabetic
Retin...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER14
08.00 – 10.00
FREE PAPER SESSION
Quick Fire Free Paper Session 1
Venu...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 15
08.45 – 18.30
INSTRUCTIONAL COURSE
Update on Posterior Uveitis
Boule...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER16
08.30 – 10.00
INSTRUCTIONAL COURSE 1
Current Management of
Uveal Mela...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 17
11.00 – 13.00
MAIN SESSION 1
Dry AMD
Auditorium (Level 0)
Chairperso...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER18
11.00 – 12.30
FREE PAPER SESSION
Quick Fire Free Paper Session 2
Venu...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 19
11.00 – 13.00
INSTRUCTIONAL COURSE 3
Current Management of Paediatri...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER20
14.00 – 16.00
MAIN SESSION 2
Diabetic Retinopathy
Auditorium (Level 0...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER 21
14.30 – 16.00
BRITISH  EIRE ASSOCIATION
OF VITREORETINAL SURGEONS
SY...
LONDON14th EURETINA Congress
THURSDAY 11 SEPTEMBER22
14.30 – 16.00
FREE PAPER SESSION
Quick Fire Free Paper Session 3
Venu...
THURSDAY 11 SEPTEMBER 23
14th EURETINA CongressLONDON
16.00 – 17.00
Opening Ceremony  EURETINA Lecture
Auditorium (Level 0...
EURETINA
DISCOVER
Visit the Resource Centre to discover the rewards
Sign up for Membership
EURETINA InSight (online intera...
FRIDAY12 September
25
14th EURETINA CongressLONDON
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER26
08.00 – 10.00
MAIN SESSION 3
Regenerative Medicine with
Presentations o...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 27
09.20	 A. Augustin GERMANY
AMD management – analysis of effectiveness ...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER28
08.00 – 09.30
AFIV-RETINA SYMPOSIUM (ASSOCIATION
FRANCO ISRAELI FOR VIS...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 29
08.00 – 09.30
INSTRUCTIONAL COURSE 7
Autofluorescence Imaging:
State-o...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER30
11.00 – 12.00
Kreissig Lecture
Auditorium (Level 0)
Chairperson: 	 I. K...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 31
11.00 – 12.30
FREE PAPER SESSION 5
Vascular Diseases and
Diabetic Reti...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER32
11.00 – 12.30
INSTRUCTIONAL COURSE 11
Laser Therapy in Retinal Disease:...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 33
11.00 – 12.30
INSTRUCTIONAL COURSE 12
Pearls  Pitfalls in the Imaging
...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER34
14.00 – 16.00
MAIN SESSION 4
The Eye  The Brain
Auditorium (Level 0)
Ch...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 35
14.30 – 16.00
EVICR.net Session
- Clinical Trial Research
Boulevard D ...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER36
14.30 – 16.00
INSTRUCTIONAL COURSE 14
Management of Proliferative
Diabe...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 37
14.30 – 16.00
INSTRUCTIONAL COURSE 15
Key Issues for SD-OCT Interpreta...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER38
16.00 – 18.00
MAIN SESSION 5
Neovascular AMD
Auditorium (Level 0)
Chair...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 39
16.30 – 18.00
ASRS SYMPOSIUM
Retina in the Future:
Where Are We Headed...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER40
16.30 – 18.00
INSTRUCTIONAL COURSE 17
Update in Ocular Oncology 2014
Bo...
LONDON14th EURETINA Congress
FRIDAY 12 SEPTEMBER 41
16.30 – 18.00
INSTRUCTIONAL COURSE 19
Update in OCT Imaging:
Indicatio...
EURETINA
Winter Meeting
Saturday 24 January 2015
5th
University of Oxford, UK
www.euretina.org
SATURDAY13 September
LONDON14th EURETINA Congress
43
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER44
08.00 – 10.00
MAIN SESSION 6
Uveal Melanoma:
Current Conflicts  Contr...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 45
08.00 – 09.30
ASIA PACIFIC VITREORETINAL SOCIETY
SYMPOSIUM (APVRS)
M...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER46
08.00 – 09.30
YOUNG EUROPEAN RETINA
SPECIALISTS SYMPOSIUM (YOURETINA)...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 47
08.00 – 09.30
INSTRUCTIONAL COURSE 20
The Intraocular Mirror Telesco...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER48
11.00 – 13.00
EURETINA Science  Medicine
Innovation Award 2014
Audito...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 49
11.00 – 12.30
FAN CLUB
Retinal Imaging Cases for Discussion
with a P...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER50
11.00 – 12.30
INSTRUCTIONAL COURSE 22
Managing Diabetic Macular Edema...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 51
11.00 – 12.30
INSTRUCTIONAL COURSE 24
Steroids in Retinal Therapy
Bo...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER52
14.00 – 16.00
ESCRS/EURETINA JOINT SYMPOSIUM
Vitreoretinal Complicati...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 53
15.50	 M. Gil, S. Pastor-Idoate, Y. D’Souza, S. Mahmood,
C. Stephen,...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER54
14.30 – 16.00
INSTRUCTIONAL COURSE 25
Eye  Brain: Retinal Nerve Fiber...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER 55
14.30 – 16.00
INSTRUCTIONAL COURSE 26
Chromovitrectomy: Novel Vital ...
LONDON14th EURETINA Congress
SATURDAY 13 SEPTEMBER56
16.00 – 18.00
MAIN SESSION 7
IMAGING
Boulevard C (Level 1)
Chairperso...
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Eurentina 2014 - London - Final programme
Próximos SlideShares
Carregando em…5
×

Eurentina 2014 - London - Final programme

2.635 visualizações

Publicada em

  • Seja o primeiro a comentar

  • Seja a primeira pessoa a gostar disto

Eurentina 2014 - London - Final programme

  1. 1. 11-14 September 2014 LONDON 14th EURETINA Congress Programme
  2. 2. NICE 15th EURETINA Congress 17 – 20 September 2015
  3. 3. LONDON14th EURETINA Congress 1CONTENTS Board & Officers 2 Letter from the President 3 Programme Overview 4 Surgical Skills Training Courses 8 Scientific Programme – Thursday 9 Scientific Programme – Friday 25 Scientific Programme – Saturday 43 Scientific Programme – Sunday 61 E-Poster Presentations 71 Video Competition 94 General Information 98 Sponsors 100 Plan of Congress Centre 102 Plan of Exhibition 104 List of Exhibitors Booth Numbers 107 EuroTimes Satellite Education Programme 115 Index 119 Online Regististration - Social Networking - Mobile Solutions - Event Analytics Event Management Software
  4. 4. LONDON14th EURETINA Congress 2 President Francesco Bandello ITALY Vice-President Ursula Schmidt-Erfurth AUSTRIA General Secretary Sebastian Wolf SWITZERLAND Immediate Past President Gisbert Richard GERMANY Vice-President Elect Jan van Meurs THE NETHERLANDS Board Members Jose García Arumí SPAIN Frank Holz GERMANY Alistair Laidlaw UK Anat Loewenstein ISRAEL Stefan Seregard SWEDEN Ramin Tadayoni FRANCE Co-Opted Board Members Borja Corcóstegui SPAIN Morten la Cour DENMARK David Pelayes ARGENTINA Programme Committee Francesco Bandello ITALY (CHAIRMAN) Alistair Laidlaw UK Gisbert Richard GERMANY Ursula Schmidt-Erfurth AUSTRIA Jan van Meurs THE NETHERLANDS Sebastian Wolf SWITZERLAND Past Presidents Bill Aylward UK José Cunha-Vaz PORTUGAL Borja Corcóstegui SPAIN Rosario Brancato ITALY August Deutman THE NETHERLANDS BOARD OFFICERS
  5. 5. LONDON14th EURETINA Congress 3PRESIDENT’S LETTER EURETINA Temple House Temple Road Blackrock Co. Dublin Ireland Tel: + 353 1 210 0092 Fax: + 353 1 209 1112 Email: euretina@euretina.org Web: www.euretina.org Dear Colleagues, On behalf of the Board and Officers of the European Society of Retina Specialists, it is my pleasure to welcome you to London for the 14th EURETINA Congress. We are delighted to once again partner our annual congress with that of ESCRS and EuCornea. I believe that the combination of three superior scientific programmes provides a unique forum for global networking and will make the ExCeL London a stimulating hub of research and knowledge exchange in worldwide ophthalmology. The Programme Committee has built on the enormous success of the 13th Congress in Hamburg, compiling an exciting scientific programme for London. The meeting will once again host many of the popular traditional features of the EURETINA programme, while new influences have been introduced to keep it up to date and cutting edge. It has been most rewarding to see the EURETINA Congress grow from strength to strength over the last number of years with attendance numbers steadily increasing each year. This is thanks to the participation of highly regarded speakers and the willingness of so many delegates to travel to hear their contributions. EURETINA is most grateful as always to the Industry for their continued support through participation in the exhibition and satellite symposia, as well as through sponsorship of various aspects of the meeting. I wish you a wonderful congress and hope that you enjoy your stay in London. Yours sincerely, Francesco Bandello President of EURETINA Chairman of the Programme Committee
  6. 6. LONDON14th EURETINA Congress 4 PROGRAMME OVERVIEW THURSDAY11SEPTEMBER 08.00 09.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 FREEPAPER1 VitreoretinalSurgeryI MAINSESSION1 DryAMD MAINSESSION2 DiabeticRetinopathy OPENINGCEREMONY WELCOMERECEPTION FREEPAPER2 VascularDiseases DiabeticRetinopathyI GERMAN RETINASOCIETY TreatmentofRetinal Disease BEAVRSSYMPOSIUM RetinalDetachment Outcomes INDUSTRYSPONSORED SATELLITEMEETING QUICKFIREFREE PAPER1 QUICKFIREFREE PAPER3 QUICKFIREFREE PAPERS2 RETINAL DETACHMENT COURSE COURSE1 CurrentManagement ofUvealMelanoma COURSE3 CurrentManagementof PaediatricVRDiseases COURSE5 FluorosceinICG- Angiography INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING COURSE2 TheRole oftheVitreous COURSE4 3DVideoCourse: 25–27GSurgery COURSE6 MinimalInvasive Vitrectomy SURGICALSKILLS COURSES AUDITORIUM LEVEL0 BOULEVARDC LEVEL1 BOULEVARDD LEVEL1 BOULEVARDE LEVEL1 BOULEVARDH LEVEL1 BOULEVARDG LEVEL1 BOULEVARDI LEVEL1 WETLABROOMS LEVEL1 UVEITISCOURSE P.12 P.17 P.20 P.23 P.21P.22 P.20P.21 P.13 P.17 P.14 P.18 P.10 P.16P.15P.16 P.19 P.8 P.19
  7. 7. LONDON14th EURETINA Congress 5PROGRAMME OVERVIEW FRIDAY12SEPTEMBER 08.00 09.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 MAINSESSION3 RegenerativeMedicine GeneTherapy KREISSIGLECTURE AMSTERDAM RETINADEBATE MAINSESSION4 TheEyeBrain MAINSESSION5 NeovascularAMD FREEPAPER3 AMDI FREEPAPER4 AMDII AFIVFRENCH ISRAELISOCIETY COURSE7 Autofluorescence Imaging:State-of-the-Art COURSE8 Electrophysiology COURSE9 NewStrategies inOcularTrauma FREEPAPER5 VascularDiseases DiabeticRetinopathyII FREEPAPER6 ImagingI COURSE10 State-of-the-Artin Anti-VegFTherapy COURSE11 LaserTherapyinRetinal Disease COURSE12 ImagingofPosterior Fundus COURSE13 MacularDystrophies SURGICAL SKILLS COURSES INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING FREEPAPERS7 VitreoretinalSurgeryII EVICR.NET ClinicalTrialResearch BIO-ENGINEERING SOCIETY FutureofVRSurgery COURSE14 ProliferativeDiabetic Retinopathy COURSE15 SD-OCTInterpretation COURSE16 Uveitis:Diagnosis Therapyin2014 FREEPAPERS8 ImagingII FREEPAPERS9 VascularDiseases DiabeticRetinopathyIII ASRS RetinaintheFuture: WhereAreWeHeaded? COURSE17 UpdateinOcular Oncology2014 COURSE18 SubthresholdLaser Surgery Course19 UpdateinOCTImaging INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING AUDITORIUM LEVEL0 BOULEVARDC LEVEL1 BOULEVARDD LEVEL1 BOULEVARDE LEVEL1 BOULEVARDH LEVEL1 BOULEVARDG LEVEL1 BOULEVARDI LEVEL1 WETLABROOMS LEVEL1 GENERALASSEMBLY (Membersonly) P.26 P.30P.31 P.35 P.38 P.31 P.35 P.39 P.32 P.36 P.39 P.32 P.36 P.40 P.33 P.37 P.40 P.33 P.8 P.37 P.41 P.34 P.34 P.38 P.26P.27P.28P.29P.29P.30
  8. 8. LONDON14th EURETINA Congress 6 PROGRAMME OVERVIEW SATURDAY13SEPTEMBER 08.00 09.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 MAINSESSION6 UvealMelanoma EURETINA ScienceMedicine InnovationAward 2014 ESCRS/EURETINA VRComplications ofAnteriorSegment Surgery CLUBJULESGONIN MinimalMaximal Surgery ASIA/PACIFICVRS Maculopathyinthe AsianPopulation FREEPAPERS10 VitreoretinalSurgeryIII YOUNGEUROPEAN RETINAL SPECIALISTS (YOURETINA) COURSE20 IntraocularMirror Telescope COURSE21 Submacular HaemorrhagesAMD FREEPAPERS12 NewDrugTreatment EVER ImagingofOcular Fundus FANCLUBFREEPAPERS11 Miscellaneous COURSE22 ManagingDME: PearlsPitfalls COURSE23 VitreoretinalInterface COURSE24 SteroidsinRetinal Therapy INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING FREEPAPERS14 VascularDiseases DiabeticRetinopathyIV FREEPAPERS13 ImagingIII RETINAWS Misadventuresinthe OperatingRoom COURSE25 EyeBrain:RNFL Analysis COURSE26 Chromovitrectomy: NovelVitalDyes COURSE27 IntraocularPseudo Tumours COURSE28 Pathology MAINSESSION7 ImagingEUROLAM UnusualCaseStudies COURSE29 MacularEdema COURSE30 RetinalTreatment Modalities COURSE31 SurgicalApproachof VRInterface Course32 VRComplicationsof CataractSurgery INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING INDUSTRYSPONSORED SATELLITEMEETING AUDITORIUM LEVEL0 BOULEVARDF LEVEL1 BOULEVARDC LEVEL1 BOULEVARDD LEVEL1 BOULEVARDE LEVEL1 BOULEVARDH LEVEL1 BOULEVARDG LEVEL1 BOULEVARDI LEVEL1 P.47P.44 P.48 P.53 P.56 P.45 P.49P.50P.51P.51 P.54P.54P.55P.55P.56P.52 P.57P.58P.58P.59P.59P.57 P.45 P.49 P.46P.47P.44 P.48 P.52
  9. 9. LONDON14th EURETINA Congress 7PROGRAMME OVERVIEW SUNDAY14SEPTEMBER 08.00 09.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 MAINSESSION8 PVRInnovation inRetinal DetachmentSurgery FREEPAPERS15 VascularDisaeases DiabeticRetinopathyV QUICKFIRE FREEPAPERS4 ESASO NewConcepts inVRSurgery COURSE34 ABCinOphthalmic Publishing COURSE35 PVRManagement Update MAINSESSION9 VeinOcclusion SPANISHVR SOCIETY PathologicMyopia COURSE36 ManagingComplications inVRSurgery COURSE33 ManagementofRetinal VascularOcclusion COURSE37 OptimisingInjection Clinics COURSE38 DiabeticEyeScreeningFREEPAPERS16 VitreoretinalSurgeryIV QUICKFIRE FREEPAPERS5 BOULEVARDC LEVEL1 BOULEVARDD LEVEL1 BOULEVARDB LEVEL1 BOULEVARDE LEVEL1 BOULEVARDH LEVEL1 BOULEVARDG LEVEL1 BOULEVARDI LEVEL1 P.62P.62P.63P.64 P.67P.67P.68P.69P.70P.70 P.65P.65P.66 P.66
  10. 10. LONDON14th EURETINA Congress 8 SURGICAL SKILLS TRAINING COURSES Surgical Skills Training Courses Chairperson: S. Binder AUSTRIA Instructors: I. Krebs AUSTRIA K. Krepler AUSTRIA U. Stolba AUSTRIA Thursday 11 September Course No. Course Name Course Time Room 01 First Steps in Vitreoretinal Surgery 09.00 – 12.00 Wetlab Room 1 (Level 1) 02 First Steps in Vitreoretinal Surgery 09.00 – 12.00 Wetlab Room 2 (Level 1) 03 Combined Anterior Posterior Segment Surgery 13.00 – 16.00 Wetlab Room 1 (Level 1) Friday 12 September Course No. Course Name Course Time Room 04 Intraocular Tamponades 09.00 – 12.00 Wetlab Room 1 (Level 1) 05 Intravitreal Injection 12.00 – 13.00 Wetlab Room 2 (Level 1) First Steps in Vitreoretinal Surgery (Course 1 2) First steps with 20g or 23g techniques explained step by step and practiced on pigs’ eyes. Participants should have some experience in anterior segment microsurgery. Combined Anterior and Posterior Segment Surgery (Course 3) The combined procedure including cataract surgery, IOL implantation and 23g vitrectomy are demonstrated and practiced on pigs’ eyes. Participants should have skills in anterior segment surgery or should have participated in Courses 1 or 2. Intraocular Tamponades (Course 4) Various vitreous tamponades, their properties and indications are demonstrated. The exchange techniques are explained and practiced on pigs’ eyes. Participants should be skilled in anterior segment surgery or should have participated in Courses 1 or 2. Intravitreal Injection (Course 5) This technique is demonstrated and practiced on pigs’ eyes. Participants do not need microsurgical experience.
  11. 11. THURSDAY11 September LONDON 9 14th EURETINA Congress
  12. 12. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER10 08.00 – 16.00 104TH RETINAL DETACHMENT COURSE Diagnostics, Options for Repair: The Diabetic Eye Boulevard H (Level 1) Cost: €120 08.00 Welcome I. Kreissig GERMANY 1. Diagnostics: Rhegmatogenous Primary Retinal Detachment Moderators: I. Kreissig GERMANY F. LaFranco USA 1.1 The 4 rules to find the primary break I. Kreissig GERMANY 1.2 A detachment without a break: what to try first? U. Mester GERMANY 2. Cerclage with Drainage 2.1 A look at cerclage after 50 years: indications, complications, long-term results I. Kreissig GERMANY 3. Minimal Segmental Buckling with Sponge (s) Without Drainage 3.1 Indications, optimal tamponade of break(s), video of surgery, complications, long-term results F. LaFranco USA 3.2 Complications and long-term anatomical and functional results S. Mennel AUSTRIA 3.3 Differential diagnosis of residual fluid J. Jonas GERMANY 4. Minimal Segmental Buckling with Temp. Buckle Without Drainage Moderators: S. Yamamoto JAPAN G. Richard GERMANY 4.1 Application, indications, video of surgery, complications, long-term results I. Kreissig GERMANY 5. Gas Operations 5.1 Perfluorocarbon gases: Physical properties; intra and postoperative complications V. Ferrara ITALY 5.2 Pneumatic retinopexy for uncomplicated detachments T. Boeker GERMANY 10.30 Coffee Break 10.55 6. Primary Vitrectomy Moderators: B. Aylward UK U. Mester GERMANY 6.1 Rationale, indications, complications, long-term results S. Mennel AUSTRIA 7. Minimal Segmental Buckling for Complicated Detachments 7.1 Reoperation: The 4 rules to find the undetected break I. Kreissig GERMANY 7.2 How to minimize risk of PVR N. Sivkova BULGARIA 7.3 PVRC1/C2 detachments. Try buckling first: Long-term visual results P. Stanga UK 8. Fellow Eye of Retinal Detachment Moderators: T. Boeker GERMANY S. Mennel AUSTRIA 8.1 Lattice degeneration and breaks in fellow eye: What to do or not do? B. Aylward UK 9. Vitrectomy for Vitreoretinal Problems 9.1 Macular hole: When and how to treat? Complications, long-term results S. Yamamoto JAPAN 9.2 Comparison of 20, 23, 25gauge vitrectomy: Indications, complications, results J. Schmidt GERMANY 12.40 Group Photo 13.00 Lunch Break
  13. 13. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 11 14.00 10. The Diabetic Eye Moderators: F. LaFranco USA J. Schmidt GERMANY 10.1 Classification of diabetic retinopathy B. Stoffelns GERMANY 10.2 Laser coagulation: When to do ? U. Vossmerbaeumer GERMANY 10.3 Intravitreal pharmacotherapy: When to do ? F. LaFranco USA 10.4 Vitrectomy in the diabetic eye: Indications, complications, long-term results G. Richard GERMANY 11. Comparison of Present Techniques for Repair of Primary Retinal Detachment 11.1 Temporary balloon buckle vs. pneumatic retinopexy vs. segmental buckling vs. primary ppv T. Boeker GERMANY 12. Various 12.1 Misdiagnosis of retinaschisis I. Kreissig GERMANY 12.2 Ambulatory double patching B. Stoffelns GERMANY 13. Case Presentations Moderator: I. Kreissig GERMANY Organiser: T. Boeker GERMANY Panel: B. Aylward UK V. Ferrara ITALY S. Mennel AUSTRIA U. Mester GERMANY G. Richard GERMANY J. Schmidt GERMANY N. Sivkova BULGARIA P. Stanga UK U. Vossmerbaeumer GERMANY S. Wolf SWITZERLAND S. Yamamoto JAPAN 14. Distribution of Diplomas 16.00 End of Course
  14. 14. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER12 08.00 – 10.00 FREE PAPER SESSION 1 Vitreoretinal Surgery I Venue: Auditorium (Level 0) Chairpersons: M. De Smet GERMANY S. Rizzo SPAIN 08.00 E. Zrenner, K. Bartz-Schmidt, F. Gekeler, T. Jackson, R. MacLaren, S. Katarina GERMANY Visual outcome in 29 blind retinitis pigmentosa patients with electronic subretinal implant Alpha-IMS 08.08 J. Pournaras, T. Wolfensberger, C. Salvisberg, C. Fouda, A. Hainard, N. Turck SWITZERLAND Vitreous proteomic analysis- new markers for vitreoretinal diseases? 08.16 E. Van Zeeburg, H. de Jong, M. Cereda, M. Van Velthoven, K. Vermeer, J. van Meurs THE NETHERLANDS A randomized controlled trial comparing intravitreal versus subretinal injection of recombinant tissue plasminogen activator for displacement of an acute submacular haemorrhage in age-related macular degeneration 08.24 P. Banerjee, W. Xing, C. Bunce, A. Chandra, D. Charteris UK A pilot study of intraocular use of intensive anti- inflammatory- triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma- the adjuncts in ocular trauma (AOT) trial 08.32 L. Lytvynchuk, A. Sergiienko, I. Savytska, G. Petrovski UKRAINE Cytological study of needle tip aspirates after intravitreal injection in rats 08.40 M. Dogramaci, T. Williamson, M. Bayazit, A. Cunningham UK Understanding unintentional retinal shift after pars plana vitrectomy (PPV) for retinal detachment (RRD) through surgical reverse engineering (SRE) technology. Phase 3 results (data processing) 08.48 W. Lam, L. Zhao, E. Mandelcorn, P. Kertes, R. Devenyi, M. Mandelcorn CANADA A prospective randomized clinical study comparing topical nepafenac sodium 0.1% versus intra-operative intravitreal triamcinolone acetate versus placebo in vitrectomy surgery for macular edema 08.56 P. Tranos, S. Asteriades, T. Vakalis, S. Koukoula, G. Perganda GREECE The role of internal limiting membrane peeling in epiretinal membrane surgery. A randomized controlled trial 09.04 P. Stalmans, J. Van Calster BELGIUM Ocriplasmin in the clinical setting- an overview of post- approval safety outcomes 09.12 A. Chandra, J. Smith, J. Kam, B. Wang, E. Kurniawan, S. Sandhu, P. Allen AUSTRALIA Endophthalmitis after pars plana vitrectomy - a 15 year prospective study 09.20 S. Ganesan, T. Sharma INDIA Endophthalmitis in full term neonates presenting as the diagnostic feature of septicemia 09.28 Y. Luo, Z. Mclelland, L. da Cruz UK Positive central scotomas observed after routine macula- on retinal detachment surgery 09.36 A. Gomaa, Y. Hegazy EGYPT Role of intra-vitreal bevacizumab in prevention of post-operative vitreous hemorrhage following pars plana vitrectomy for complications of proliferative diabetic retinopathy 09.44 C. Geenen, M. Dogramaci, T. Williamson UK The risk factors and the outcome of iatrogenic retinal breaks during pars plana vitrectomy for rhegmatogenous retinal detachment 09.52 J. Bouchepillon, P. Koehrer, C. Binquet, C. Tzourio, A. Bron, C. Creuzot-Garcher FRANCE Analysis of the vitreomacular interface in a French population-based study (The Montrachet study- maculopathy, optic nerve, nutrition, neurovascular and heart diseases) 10.00 End of session
  15. 15. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 13 08.00 – 10.00 FREE PAPER SESSION 2 Vascular Diseases Diabetic Retinopathy I Venue: Boulevard C (Level 1) Chairpersons: B. Corcóstegui ITALY S. Wolf SWITZERLAND 08.00 F. Bandello, A. Augustin, D. Boyer, R. Belfort, Y. Yoon, R. Maturi, S. Whitcup ITALY 3-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (MEAD study) 08.08 U. Chakravarthy UK Long-term visual outcomes based on baseline vision in patients with chronic diabetic macular edema (DME) treated with fluocinolone acetonide (FAc) 08.16 B. Kuppermann, B. Ding, I. Stoilov USA Anti-VEGF treatments for diabetic macular edema- comparison of phase III randomized controlled clinical studies 08.24 R. Leite, N. Gomes, L. Mendonça, K. Sousa, G. Santos, R. Gentil, F. Vaz PORTUGAL Choroidal thickness in patients with diabetic retinopathy 08.32 C. Lobo, S. Nunes, M. Costa, M. Simões, C. Egas, C. Faro, J. Cunha-Vaz PORTUGAL Different phenotypes on non-proliferative diabetic retinopathy associated with different genetic polymorphisms 08.40 E. Midena, J-F. Korobelnik ITALY Impact of baseline visual acuity on visual and anatomical outcomes in patients with diabetic macular edema (DME) treated with intravitreal aflibercept (IVT-AFL)- data from the VIVID/VISTA-DME studies 08.48 E. Midena, J-F. Korobelnik ITALY Intravitreal aflibercept for diabetic maculer edema (DME) – 100-Week results from the VIVID-DME and VISTA-DME studies 08.56 J-F. Korobelnik, L. Kodjikian, C. Delcourt, V. Gualino, R. Leaback, M. Velard FRANCE Multicentre longitudinal study of the use of dexamethasone intravitreal implant for treatment of macular edema due to retinal vein occlusion in the French clinical setting- an interim analysis 09.04 I. Kozak, J. Arevalo, V. Gupta, J. Chhablani, J. Kim SAUDI ARABIA Targeted retinal photocoagulation (TRP) using navigation- new technique 09.12 D. Alonistiotis, A. Takis, E. Kontou, D. Panagiotidis, N. Ioannou, D. Papaconstaninou, P. Theodossiadis GREECE Comparison and follow up of the retinal nerve fiber layer of diabetic patients type II, with normal subjects of the same age and gender 09.20 R. Belfort, The Ozurdex MEAD Study Group BRAZIL Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant- MEAD study findings 09.28 M. Gillies, S Fraser-Bell, L. Lim, A. Campain, W. Salem, C. Aroney, I. McAllister AUSTRALIA Randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema. The BEVORDEX study 09.36 B. Burton UK Baseline characteristics of patients with retinal vein occlusion enrolled within the LUMINOUS study 09.44 S. Vujosevic, M. Berton, S. Bini, E. Convento, F. Martini, E. Midena ITALY Choroidal and retinal modifications after anti-VEGF treatment in center involving diabetic macular edema 09.52 L. Pierro, C. La Spina, C. Del Turco, M. Gagliardi, G. Casalino, M. Battaglia Parodi, F. Bandello ITALY Inner retinal layers changes in diabetic retinopathy (DR)- a spectral domain OCT (SDOCT) study 10.00 End of session
  16. 16. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER14 08.00 – 10.00 FREE PAPER SESSION Quick Fire Free Paper Session 1 Venue: Boulevard D (Level 1) Chairpersons: J. García Arumí SPAIN A. Sharma INDIA 08.00 J. Gonzalez-Lopez, B. Arya, P. Addison UK Earliest real-life experience using lucentis for macular edema secondary to branch retinal vein occlusion in the national health service (NHS)- bravo? 08.05 D. Chakraborty, T. Sinha, A. Das, S. Boral, B. Dutta-Choudhury INDIA Managing anti-VEGF resistance in diabetic macular edema 08.10 A. Korol, O. Zadorozhnyy, T. Kustryn, I. Nasinnyk UKRAINE New indications for aflibercept in patients with neovascularisation 08.15 K. Nabawi, A. Sharaf, H. Sowelam EGYPT Short-term results of intravitreal ranibizumab injection in eyes with diabetic macular edema 08.20 R. Narayanan, J. Chhablani, I. Kozak, G. Jonnadula, A. Venkata, R. Pappuru, P. Rao INDIA Choroidal thickness in macular telangiectasia type 2 08.25 H. Al-Nashar EGYPT Evaluation of topical alpha-2 agonist in the treatment of mixed diabetic maculopathy 08.30 R. Hillier, E. Ojaimi, D. Wong, A. Berger, S. Boyd, R. Kohly, R. Muni UK Aqueous cytokine levels as indicators of disease severity and predictors of treatment response to ranibizumab in diabetic macular edema 08.35 L. Hattenbach, N. Eter, H. Hans, N. Feltgen, L. Gabriele, G. Lambrou, T. Knorr GERMANY Efficacy and safety of 0.5 mg ranibizumab compared with intravitreal implant containing 0.7 mg dexamethasone in patients with branch retinal vein occlusion over 6 months 08.40 S. Theodoropoulou, O. Bartfai, R. Johnston, A. Sallam UK Dexamethasone implant in retinal vein occlusion- efficacy and safety using repeat injections as needed 08.45 K. Xue, E. Yang, V. Chong UK Ultra-widefield fundus fluorescein angiography reveals distinct mechanisms of diabetic macular edema and helps to predict response to ranibizumab treatment 08.50 G. Bikbova, T. Oshitari, S. Yamamoto JAPAN Regenerative effect of range neurotrophic factors in high dose AGEs exposed isolated rat retinas 08.55 M. Kernt GERMANY Combination of navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema- 2 year results 09.00 J. Garweg, M. Halberstadt SWITZERLAND Outcome of vitrectomy for suprachoroideal hemorrhage 09.05 V. Agrawal, K. Khilnani, R. Saini, A. Singh INDIA Retinal detachment associated with coloboma of choroid-management strategies and outcome 09.10 L. Akhundova, M. Karimov AZERBAIJAN Supplemental scleral buckling for rhegmatogenous retinal detachment with a high risk proliferative vitreoretinopathy 09.15 N. Acar TURKEY A new foreign body forceps designed for the removal of most types of intraocular foreign bodies 09.20 R. Troyanovsky, B. Monakhov, A. Baranov, S. Solonina, O. Sinyavskiy, A. Golovin, N. Malinovskaya RUSSIA Perforating open globe injuries- epidemiology, diagnosis and management 09.25 J. Nobre-Cardoso, A. Cardoso, N. Marques, A. Miranda, B. Beltrán, J. Silva, N. Campos Portugal Vitreoretinal interface features on spectral domain optical coherence tomography of fellow eyes of patients with idiopathic macular holes 09.30 J. Figueira, I. Laíns, D. Sousa Martins, J. Lencart, R. Belfort, M. Maia PORTUGAL Efficacy and safety analysis of intraocular lutein-based dyes for vitreoretinal surgery in preclinical and clinical models 09.35 F. Rodrigues, R. Almeida, F. Trindade, R. Pereira, S. Moniz PORTUGAL Retinal detachment epidemiology in Madeira Island 09.40 C. Sinapis, R. Newsom, S. Lash, D. Hornan, A. Warwick, P. Alexander UK Vitrectomy in diabetic patients- the fellow eye 09.45 C. de Giacinto, R. Piermarocchi, D. Minutola, D. Tognetto ITALY The spontaneous closure, reopening and the further spontaneous closure of a stage IV full-thickness idiopathic macular hole- a case report 10.00 End of session
  17. 17. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 15 08.45 – 18.30 INSTRUCTIONAL COURSE Update on Posterior Uveitis Boulevard E (Level 1) Course Organisers: C.P. Herbort SWITZERLAND C. Pavesio UK Cost: €120 I. Diagnosis, Work-up Investigational Procedures 08.45 P. Murray UK Introduction: Clinical assessment of posterior uveitis 09.10 A. Denniston UK Investigational work-up of posterior uveitis 09.30 C.P. Herbort SWITZERLAND Angiographic work-up for posterior uveitis 09.55 P. Neri ITALY OCT in posterior uveitis 10.10 A. Mantovani ITALY Autofluorescence and infrared imaging in uveitis 10.30 Discussion 10.40 Coffee Break II. Main Entities IIa. Infectious 11.00 C. Pavesio UK Toxoplasmosis 11.18 M. Westcott UK Viral retinitis 11.36 M. Stanford UK Tuberculosis 11.54 P. Kestelyn BELGIUM Syphilis 12.12 Discussion IIb1. Non-infectious 12.15 M. Stanford UK Behçet 12.35 C.P. Herbort SWITZERLAND Choriocapillaritis – MEWDS APMPPE Multifocal choroiditis 13.00 Discussion 13.10 Lunch Break IIb2. Non-infectious 14.10 M. Westcott UK Serpiginous choroidopathy 14.25 P. Kestelyn BELGIUM Stromal choroiditis I: VKH SO 14.40 P. LeHoang FRANCE Stromal choroiditis II: Birdshot 14.55 N. Jones UK Sarcoidosis 15.10 P. LeHoang FRANCE Masquerades 15.40 Discussion 15.50 Coffee Break III. Treatment, Complications Surgery 16.10 C. Pavesio UK Local therapies in posterior uveitis 16.26 P. Murray UK Steroids and immunosuppressives 16.42 A. Denniston UK Biologics 16.58 Discussion IV. Complications Surgery 17.00 P. Neri ITALY CMO 17.15 N. Jones UK Cataract 17.35 P. LeHoang FRANCE Glaucoma 17.55 L. da Cruz UK Vitreoretinal Surgery 18.10 Discussion 18.30 End of Session
  18. 18. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER16 08.30 – 10.00 INSTRUCTIONAL COURSE 1 Current Management of Uveal Melanoma Boulevard G (Level 1) Course Organiser: D.E. Pelayes ARGENTINA Cost: €25 08.30 D.E. Pelayes ARGENTINA FNAB and biopsy 08.39 N. Bechrakis AUSTRIA Clinical presentation and differential diagnosis of pseudeomelanomas 08.48 S. Seregard SWEDEN Brachytherapy 08.57 L. Zografos SWITZERLAND Proton Beam radiotherapy of uveal melanomas 09.06 M. Foerster GERMANY Iris melanomas 09.15 L. Desjardins FRANCE Epidemiology 09.24 N. Bornfeld GERMANY Endoresection 09.33 E. Midena ITALY Metastatic uveal melanoma 09.42 S. Coupland UK Pathology 09.51 Discussion 10.00 End of course 08.30 – 10.00 INSTRUCTIONAL COURSE 2 The Role of the Vitreous in Retinal Disease Boulevard I (Level 1) Course Organiser: E. Stefánsson ICELAND  Cost: €25 08.30 J. Sebag USA Vitreous structure and the influence of anomalous posterior vitreous detachment on retinal disease 08.45 E. Stefánsson ICELAND Vitreous physiology and retinal disease 09.00 E. Stefánsson ICELAND Cataract formation and vitreous 09.15 M. Trese USA Vitreolysis 09.30 A. Augustin GERMANY Clinical treatment of vitreal disease 09.45 Discussion 10.00 End of course
  19. 19. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 17 11.00 – 13.00 MAIN SESSION 1 Dry AMD Auditorium (Level 0) Chairpersons: J. García Arumí SPAIN U. Schmidt-Erfurth AUSTRIA 11.00 C. Chan USA Aging, degeneration, inflammation, apoptosis: mechanisms of AMD 11.20 E. Souied FRANCE Drusen, pseudodrusen, ghost drusen: origins and outcomes 11.40 U. Schmidt-Erfurth AUSTRIA Imaging and quantification of RPE and photoreceptor disease 12.00 C. Toth USA (FOR THE AREDS 2 OCT GROUP) Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging 12.20 Z. Yehoshua USA Complement inhibition in the treatment of AMD 12.40 R. MacLaren UK Current horizon of transplantation, stem cell and gene therapy 13.00 End of session 11.00 – 12.30 GERMAN RETINA SOCIETY SYMPOSIUM Common Misconceptions Mistakes in the Treatment of Retinal Diseases Boulevard C (Level 1) Chairpersons: H. Heimann GERMANY D. Pauleikhoff GERMANY 11.00 S. Schmitz-Valckenberg GERMANY The 5 most common mistakes in OCT interpretation 11.15 D. Pauleikhoff GERMANY The 5 most common mistakes in prn treatment of exudative age related macular degeneration 11.30 H. Helbig GERMANY The 5 most common mistakes in the treatment of diabetic retinopathy 11.45 N. Bornfeld GERMANY The 5 most common mistakes in ocular oncology 12.00 H. Heimann GERMANY The 5 most common mistakes in the treatment of retinal breaks and retinal detachment 12.15 C. Eckardt GERMANY The 5 most common mistakes in vitreoretinal surgery 12.30 End of symposium
  20. 20. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER18 11.00 – 12.30 FREE PAPER SESSION Quick Fire Free Paper Session 2 Venue: Boulevard D (Level 1) Chairpersons: P. LeHaong FRANCE E. Stefánsson ICELAND 11.00 A. Caramoy, K. Droege, B. Kirchhof, S. Fauser GERMANY Retinal layers measurements in healthy eyes and in eyes receiving silicone oil-based endotamponade 11.05 M. Bhende, M. K P INDIA Effect of ocular magnification on measurements made on spectral domain optical coherence tomography 11.10 A. Mathai, M. Nicholson, R. Reddy Pappuru INDIA Fundus autofluorescence abnormalities in acute central serous chorioretinopathy and its diagnostic accuracy to detect the area of RPE leak 11.15 G. Satirtav, G. Kaya, M. Donbaloglu, H. Kerimoglu, R. Oltulu TURKEY Evaluation of choidal thickness in relation to gender, age, axial length and refractive error in young Turkish population 11.20 E. Merce, M. Fortane FRANCE Bilateral chorioretinal folds associated with a fourth- ventricular ependymoma 11.25 C. Ferreira, J. Beato, M. Falcão, E. Brandão, Â. Carneiro, F. Falcão-Reis PORTUGAL Choroidal thickness in multisystemic autoimmune diseases under hydroxychloroquine treatment without ophthalmologic manifestations 11.30 R. Rothwell, D. Meira, M. Oliveira, L. Ribeiro, S. Fonseca PORTUGAL Evaluation of choroidal thickness during pregnancy using enhanced depth imaging optical coherence tomography 11.35 I. Panova, M. Prokopieva, N. Varnavskaya RUSSIA OCT-monitoring of various ethiology chorioretinitis 11.40 I. Panova, O. Avdeeva, N. Varnavskaya RUSSIA OCT-verification of activity the various ethiology chorioretinitis 11.45 A. El Habbak, M. Nagy EGYPT Silicone oil 1000 Cs and 2000 Cs tamponade is nearly as effective as silicone 5000 Cs in pars plana vitrectomy with less complications 11.50 S. Jordan, O. Garcia-Garcia, O. Subirà, H. Brosa, S. Jordán SPAIN Vogt-Koyanagi-Harada syndrome- a review of 32 cases diagnosed in our area 11.55 M. Tikhonovich, S. Gavrilova RUSSIA A rat model of proliferative vitreoretinopathy induced by dispase 12.00 S. Soedarman, A. Djatikusumo, S. Widyawati, A. Setiawati INDONESIA The effect of prophylactic nepafenac 0,1% eye drops on macular changes after phacoemulsification for non- proliferative diabetic retinopathy patients in Indonesia- a preliminary report 12.05 S. Zanak INDIA Correlation of optical coherence tomography measured retinal nerve fiber layer thickness with refractive status of the eye 12.10 A. Sharma, J. Sheth, M. RJ, V. N, S. SK, J. Patil INDIA Characteristics of central serous retinopathy (CSR) with pigment epithelial detachment (PED) and without PED in Asian Indians 12.15 K. Ghasemi Falavarjani, M. Modarres, M. Parvaresh, M. Hashemi, M. Naseripour, A. Hadavand Khani IRAN Intra-silicone oil injection of methotrexate at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy 12.30 End of session
  21. 21. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 19 11.00 – 13.00 INSTRUCTIONAL COURSE 3 Current Management of Paediatric Vitreoretinal Diseases Boulevard G (Level 1) Course Organisers: A. Kychenthal CHILE G. Caputo FRANCE Cost: €25 11.00 M. Trese USA Current management of ROP 11.15 C. Wong UK Familial exudative vitreoretinopathy and retinoschisis 11.30 P. Dorta CHILE Paediatric retinal imaging 11.45 K. Tawansy USA Type 1 ROP: current management (laser-antiVEGF) 12.00 A. Kychenthal CHILE ROP retinal detachment 12.15 G. Caputo FRANCE Coats disease persistent fetal vasculature syndrome (PFV) 12.30 M. Shapiro USA Paediatric rhegmatogenous retinal detachment 12.45 Discussion 13.00 End of course 11.00 – 13.00 INSTRUCTIONAL COURSE 4 The First 3D Video Course on Current Wide Angle 25-27G Surgery Including Guidelines for 3D Teaching Videos in Vitreoretinal Surgery Boulevard I (Level 1) Course Organisers: A. Nikolakopoulos GREECE T. Aaberg USA C. Riemann USA Cost: €25 11.00 M. Mura THE NETHERLANDS 11.09 V. Ferrara ITALY 11.18 S. Kaynak TURKEY 11.27 F. Balta ROMANIA 11.36 C. Forlini ITALY 11.45 K. Kandonosono JAPAN 11.54 F. Boscia ITALY 12.03 S. Gotzarides GREECE 12.12 S. Rizzo ITALY 12.21 C. Claes BELGIUM 12.30 F. Fayyad JORDAN 13.00 End of course
  22. 22. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER20 14.00 – 16.00 MAIN SESSION 2 Diabetic Retinopathy Auditorium (Level 0) Chairpersons: F. Bandello ITALY J. Cunha-Vaz PORTUGAL 14.00 M. Porta ITALY From bench to slit lamp 14.20 E. Stefánsson ICELAND The EURETINA project for diabetic retinopathy screening 14.40 J. Cunha-Vaz PORTUGAL Genotype and phenotype associations in diabetic retinopathy 15.00 R. Simo SPAIN The EUROCONDOR project 15.20 M. Battaglia Parodi ITALY Novelties in the field of diabetic macular edema 15.40 S. Sivaprasad UK Recent perspectives for treatment of proliferative diabetic retinopathy 16.00 End of session 14.00 – 15.30 INSTRUCTIONAL COURSE 5 Fluorescein and ICG-Angiography in Macular Diseases: Interpretation and Comparison with Other Imaging Modalities Boulevard G (Level 1) Course Organisers: D. Pauleikhoff GERMANY G. Staurenghi ITALY Cost: €25 14.00 D. Pauleikhoff GERMANY Is fluorescein and ICG angiography in macular diseases still important? A statement towards multimodal imaging 14.13 S. Wolf SWITZERLAND Imaging tools for angiography – pros and cons 14.26 G. Staurenghi ITALY ICG angiography – indications and interpretation 14.39 F. Sallo UK Correlation of angiography, autofluorescence, OCT An example: Multimodal imaging in MacTel type 2 14.52 A. Tufail UK Angiographic assessment vs. OCT during anti-VEGF-therapy 15.05 P. Charbel Issa GERMANY Imaging macular dystrophies – novel approaches and the value of angiography 15.18 Discussion 15.30 End of course
  23. 23. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER 21 14.30 – 16.00 BRITISH EIRE ASSOCIATION OF VITREORETINAL SURGEONS SYMPOSIUM (BEAVRS) The How Why of Measuring Retinal Detachment Outcome: Introducing the EURETINA Members Retina Detachment Outcome Project Boulevard C (Level 1) Chairpersons: B. Aylward UK (PRESIDENT, BEAVRS) D. Steel UK 14.30 B. Aylward UK Background/Introduction: why should we measure complexity adjusted outcome? 14.43 T. Williamson UK Developing the RD standardised data set 14.56 S. Winder UK The EURETINA online data collection tool: demo and sign up 15.09 D. Yorston UK BEAVRS results: the first 2000 cases - complexity adjusted results 15.22 D. Steel UK Research potential and publication plans 15.35 H. Heimann GERMANY Hasn’t the EVRS done this? 15.48 B. Aylward UK Summary and sign up 16.00 End of symposium 14.00 – 15.30 INSTRUCTIONAL COURSE 6 Minimal Invasive Vitrectomy Boulevard I (Level 1) Course Organiser: C. Prünte SWITZERLAND  Cost: €25 14.00 C. Prünte SWITZERLAND Basic technical aspects of minimal invasive vitrectomy 14.18 J. García Arumí SPAIN Safety aspects of minimal invasive vitrectomy 14.36 J-F. Korobelnik FRANCE Managing diabetic retinopathy and other proliferative diseases  14.54 A. Augustin GERMANY Managing retinal detachment 15.12 Discussion 15.30 End of course
  24. 24. LONDON14th EURETINA Congress THURSDAY 11 SEPTEMBER22 14.30 – 16.00 FREE PAPER SESSION Quick Fire Free Paper Session 3 Venue: Boulevard D (Level 1) Chairpersons: C. Creuzot-Garcher FRANCE G. Querques ITALY 14.30 S. Yu, H. Kwak SOUTH KOREA Analysis of drusen volume and area changes 14.35 I. Laíns, J. Marques, M. Costa, I. Pires, M. Cachulo, J. Figueira, R. Silva PORTUGAL Retinal angiomatous proliferation - incidence and phenotype of neovascularization in the fellow-eye 14.40 J. Pinheiro-Costa, J. Costa, J. Beato, P. Freitasda-Costa, M. Falcão, F. Falcão-Reis, A. Carneiro PORTUGAL Analysis of the effects of aflibercept in chronic neovascular age-related macular degeneration previously treated with bevacizumab or ranibizumab 14.45 N. Yadav, T. Sharma, A. Banker, A. Naik, S. Sarkar INDIA Characteristics of patients with neovascular age-related macular degeneration in India - data from UNVEIL study 14.50 J. Quadrado Gil, J. Marques, I. Lains, M. Costa, S. Nunes, M. Cachulo, R. Silva PORTUGAL Reticular pseudodrusen and the 5 year risk of progression for late AMD - a multimodal imaging approach 14.55 R. Agrawal, P. Addison, G. Fernandez-Sanz, S. Bala UK Desegmentation of Ozurdex implant in vitreous cavity – report of two cases 15.00 R. Hua, R. Gangwani, L. Chen CHINA To compare Bruch membrane opening and neural canal in preperimetric glaucomatous eyes with abnormal posterior pole asymmetry analysis 15.05 L. Gopal, A. Wagle, B. Maheshwar SINGAPORE ICG findings in the fellow eye of patients with polypoidal choroidal vasculopathy 15.10 P. Guzman-Salas, E. Guinto-Arcos, M. Pedroza-Seres MEXICO Epidemiologic characteristics of patients with sympathetic ophthalmia in Mexico 15.15 C. Claes BELGIUM Ultra high speed 27G vitrectomy 15.20 M. El Rashedy EGYPT Asymmetric diabetic retinopathy and carotid insufficiency- a correlative study 15.25 A. Sharma, J. Sheth, RJ. Nadhisuden, N. Vidhya, SK. Sundaramoorthy, J. Patil INDIA Prevalence of pigment epithelial detachment (PED) in cases of central serous retinopathy (CSR) in Asian Indians 15.30 M. Kim, D. Lee, Y. Cho SOUTH KOREA Surgical outcome of simultaneous intraocular lens (IOL) rescue and sutureless intrascleral tunnel fixation of dislocated IOLs 15.35 A. Hegazy, S. Esmat, T. Macky, R. Zedan EGYPT Retinal ganglion cell complex changes using spectral domain optical coherence tomography in diabetic patients without retinopathy 15.40 W. Gan, N. Jones UK Serpiginous-like choroiditis-as a marker for tuberculosis in a non-endemic area 15.45 Z. Elhousseini, A. Laidlaw, E. Lee UK Effect of expansile gas bubble following pars plana vitrectomy on retinal displacement 15.50 A. El-Sawy Habib, H. Makled EGYPT A prospective randomized study on the role of viscoadaptive OVD Healon5 versus combining viscodispersive-viscocohesive OVDs (soft-shell technique) in protecting the corneal endothelium during phacoemulsification of hard cataract 15.55 S. Mahapatra, G. Kanungo INDIA Retinal angiomas- a case series 16.00 End of session
  25. 25. THURSDAY 11 SEPTEMBER 23 14th EURETINA CongressLONDON 16.00 – 17.00 Opening Ceremony EURETINA Lecture Auditorium (Level 0) Chairperson: F. Bandello ITALY 16.00 Welcome from the President F. Bandello ITALY (PRESIDENT, EURETINA) 16.10 The EURETINA Lecture 2014 Donated by the Claere Jung Foundation, Hamburg Gene Therapy for Retinal Disease – What Lies Ahead R. MacLaren UK Presentation of Certificate S. Wolf SWITZERLAND (GENERAL SECRETARY, EURETINA) 16.40 EURETINA Video Competition Awards F. Bandello ITALY (PRESIDENT, EURETINA) 16.50 Closing Remarks U. Schmidt-Erfurth AUSTRIA (VICE-PRESIDENT, EURETINA) 17.00 End of Ceremony
  26. 26. EURETINA DISCOVER Visit the Resource Centre to discover the rewards Sign up for Membership EURETINA InSight (online interactive courses) EURETINA On Demand (online library of presentations from EURETINA Congresses) Find us in the exhibition hall BOOTH B01
  27. 27. FRIDAY12 September 25 14th EURETINA CongressLONDON
  28. 28. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER26 08.00 – 10.00 MAIN SESSION 3 Regenerative Medicine with Presentations on Gene Therapy Auditorium (Level 0) Chairpersons: J. Sahel FRANCE E. Banin ISRAEL 08.00 R. Ali UK Introductory overview 08.13 L. da Cruz UK Cell therapy 08.26 D. Dalkara FRANCE Vectors 08.39 Y. Arsenevic SWITZERLAND Lentiviruses 08.52 E. Banin ISRAEL Gene therapy for acromatopsia caused by mutations in the CNGA3 gene: from a large animal model to the clinic 09.05 R. MacLaren UK Photoreceptor transplantation 09.18 J. Bainbridge UK New perspectives (substrates for RPE transplantation) 09.31 J. Sahel FRANCE Gene-independent strategies to extend cone photoreceptors functional life 09.44 Discussion 10.00 End of session 08.00 – 09.45 FREE PAPER SESSION 3 AMD I Venue: Boulevard C (Level 1) Chairpersons: A. Loewenstein ISRAEL L. Mastropasqua ITALY M. Nehemy BRAZIL 08.00 M. Buckle, A. Lee, I. Stratton, R. Healey, A. Tufail, R. Johnston UK Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the UK 08.08 H. Elbaz, T. Peto, R. Höhn, G. Zur Hausen, P. Wild, A. Mirshahi, N. Pfeiffer UK Epidemiology of ophthalmic conditions and their association with ocular and systemic diseases in Germany. An interdisciplinary work within the Gutenberg health study 08.16 C. Schütze, M. Wedl, B. Baumann, M. Pircher, C. Hitzenberger, U. Schmidt-Erfurth AUSTRIA Response of the retinal pigment epithelium (RPE) to antiangiogenic therapy in neovascular age-related macular degeneration (AMD) 08.24 R. Mahdy, M. Brinkmann, Y. Miura, M. Rudolf, S. Grisanti GERMANY Evaluating pharmacologic effects of different drugs in an in-vitro model of the outer blood-retinal barrier using different microscopic techniques 08.32 H. Sharma, P. Mathewson, M. Lane, P. Shah, H. Palmer, A. Denniston, M. Tsaloumas UK The role of social deprivation in severe neovascular age related macular degeneration 08.40 A. Rosenblatt, G. Lavi, G. Rabina, R. Kehat, O. Rubalsky, A. Loewenstein, M. Goldstein ISRAEL Long term follow up of patients treated with bevacizumab for neovascular age-related macular degeneration 08.48 I. Mantel, C. Gianniou, A. Dirani, L. Jang, A. Ambresin SWITZERLAND Functional outcome of neovascular AMD with intra- or subretinal fluid refractory to monthly anti-VEGF treatment 08.56 S. Tavassoli, M. Buckle, A. Sallam, R. Johnston UK First signs of neovascular age-related macular degeneration requiring anti-VEGF treatment in second eyes under monthly surveillance after treatment in the first eye 09.04 I. Westborg, S. Albrecht, E. Granstam, G. Bjärnhall, N. Karlsson SWEDEN Endophthalmitis and safety in intravitreal treatments in Sweden - the Swedish macula register – operative routines in intravitreal treatments in Sweden 2013 09.12 J. Mones SPAIN What does early neovascular AMD look like?
  29. 29. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 27 09.20 A. Augustin GERMANY AMD management – analysis of effectiveness in the detection of CNV following the integration of the foreseehome tele-monitoring system in the management of intermediate AMD patients 09.28 U. Chakravarthy UK The home monitoring of the eye (HOME) study 09.36 A. Loewenstein (HOME Study Research Group) ISRAEL The HOME study- lesion characteristics of early CNV 09.45 End of session 08.00 – 09.45 FREE PAPER SESSION 4 AMD II Venue: Boulevard D (Level 1) Chairpersons: M. Larsen DENMARK J.C. Pastor SPAIN 08.00 M. Cachulo, I. Laíns, C. Lobo, J. Figueira, M. Costa, S. Nunes, R. Silva PORTUGAL Prevalence of age-related macular degeneration in Portugal- the Coimbra eye study 08.08 T. Jackson, A. Muldrew, T. Peto, S. Harding, J. Sahni, U. Chakravarthy UK External beam X-ray therapy for the treatment of neovascular age-related macular degeneration- 3 year safety outcomes of the INTREPID trial 08.16 C. Klaver, G. Buitendijk, N. Amin, A. Hofman, C. van Duijn, J. Vingerling THE NETHERLANDS Direct-to-consumer personal genome testing for age- related macular degeneration 08.24 H. Gerding SWITZERLAND How many injections of ranibizumab are necessary in the first year of wet AMD treatment? A meta-analysis 08.32 M. Rudolf, A. Mohi, S. Grisanti, Y. Miura GERMANY ApoA-I mimetic peptide L-4F reduces significantly lipid deposits in Bruch’s membrane and complement activation in geriatric monkeys with age-related maculopathy 08.40 E. Pras, N. Shoshany, I. Vulih, D. Volodarsky, O. Isakov, D. Kristal ISRAEL Whole exome sequencing (WES) in age-related macular degeneration (AMD) patients uncovers novel mutations in macular degeneration genes 08.48 L. Lytvynchuk, A. Sergiienko, G. Lavrenchuk, G. Petrovski UKRAINE Antiproliferative and apoptotic action of aflibercept on fibroblast-like cell strain in vitro 08.56 M. Gillies, D. Barthelmes AUSTRALIA Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors- observational study data 09.04 S. de Massougnes, A. Ambresin, W. Ferrini, I. Mantel SWITZERLAND Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration previously refractory to ranibizumab 09.12 H. Kwak, S. Yu SOUTH KOREA Five year results of combined treatment for polypoidal choroidal vasculopathy- verteporfin PDT and intravitreal anti-VEGF 09.20 S. Yu, H. Kwak SOUTH KOREA Reliability of smartphone-based electronic visual acuity testing - (applications in remote monitoring and clinical research of macular pathology)
  30. 30. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER28 08.00 – 09.30 AFIV-RETINA SYMPOSIUM (ASSOCIATION FRANCO ISRAELI FOR VISION – RETINA) Boulevard E (Level 1) Part 1: Updates in Retina Moderators: A. Loewenstein ISRAEL I. Chowers ISRAEL E. Souied FRANCE 08.00 G. Querques ITALY Black is black, grey is grey 08.06 R. Hashmonay USA Novel treatments in retinal disease 08.12 A. Loewenstein ISRAEL Early detection of AMD 08.18 L. Kodjikian FRANCE Update on H2H studies 08.24 I. Chowers ISRAEL Pharmacogenetics in AMD 08.30 E. Souied FRANCE Ghost Drusen 08.36 M. Goldstein ISRAEL Somatotype in patients with CSR 08.42 S. Razavi FRANCE Swept source and choroid 08.48 D. Weinberger ISRAEL AntiVEGF – do we inject too much? 08.54 G. Coscas FRANCE En face OCT Part 2: Pearls in Retina: Clinical Cases Moderators: M. Goldstein ISRAEL G. Querques ITALY G. Coscas FRANCE 09.00 S-Y. Cohen FRANCE Mystery case 1 09.06 M. Regenbogen ISRAEL Mystery case 2 09.12 E. Averbukh ISRAEL Mystery case 3 09.18 M. Goldstein ISRAEL Mystery case 4 09.24 Closing comments 09.30 End of symposium 09.28 J. Marques, I. Laíns, J. Figueira, C. Farinha, M. Cachulo, M. Costa, R. Silva PORTUGAL Polypoidal choroidal vasculopathy- can SD-OCT overtake indocyanine-green angiography? 09.36 A. Tufail, L. Aaron, U. Chakravarthy, P. Keane, R. Johnston, C. Egan, D. Sim UK UK neovascular AMD database study- time to reactivate after a pause in treatment - outcomes from over 92,000 intravitreal ranibizumab injections 09.45 End of session
  31. 31. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 29 08.00 – 09.30 INSTRUCTIONAL COURSE 7 Autofluorescence Imaging: State-of-the-Art Boulevard H (Level 1) Course Organiser: F. Holz GERMANY Cost: €25 08.00 S. Schmitz-Valckenberg GERMANY How to optimize autofluorescence image acquisition  08.15 F. Holz GERMANY Interpreting AF images: a practical approach 08.30 A. Tufail UK Autofluorescence imaging in inflammatory diseases  08.45 M. Fleckenstein GERMANY The role of autofluorescence in AMD  09.00 T. Theelen THE NETHERLANDS Making the correct diagnosis: macular and retinal dystrophies  09.15 Discussion 09.30 End of course 08.00 – 10.00 INSTRUCTIONAL COURSE 8 Electrophysiology: Principles Practice Boulevard G (Level 1) Course Organiser: G. Holder UK Cost: €25 08.00 G. Holder UK An introduction to the tests 08.25 B. Leroy BELGIUM Electrophysiology and inherited disease 08.50 D. Thompson UK Paediatric electrophysiology 09.15 G. Holder UK Electrophysiology in acquired and inflammatory disease 09.40 Discussion 10.00 End of course
  32. 32. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER30 11.00 – 12.00 Kreissig Lecture Auditorium (Level 0) Chairperson: I. Kreissig GERMANY Introduction F. Bandello ITALY (PRESIDENT, EURETINA) Keynote Lecture J. Seddon USA Understanding the mechanisms and etiology of macular degeneration-genetics and modifiable factors Presentation of Award I. Kreissig GERMANY 08.00 – 10.00 INSTRUCTIONAL COURSE 9 New Strategies in Ocular Trauma Boulevard I (Level 1) Course Organisers: C. Forlini ITALY A. Nikolakopoulos GREECE Cost: €25 08.00 S. Natarajan INDIA The behaviour in complicated trauma of intrascleral sutureless IOL 08.10 A. Nikolakopoulos GREECE Intrascleral acrysoft in a post traumatic aniridia, dropped nucleus and retinal detachment 08.20 P. Szurman GERMANY Iris reconstruction in traumatic aniridia 08.30 M. Forlini ITALY Case report: iris trauma – the different way of iris reconstruction 08.37 C. Forlini ITALY Artificial iris and IOL implant in pole to pole surgery in severe trauma cases 08.47 P. Sullivan UK How not to do it – mistakes in the management of severe trauma 08.57 F. Fayyad JORDAN Traumatic giant retinal tears: case reports 09.07 K. Sabti KUWAIT The use of microendoscopy in selected cases of severe posterior segment trauma 09.17 M. Nagpall INDIA IOFB removal: an assortment of cases 09.27 H. Mortada EGYPT Combined chorioretinectomy and ILM peeling for prophylaxis of recurrent proliferation in open globe injuries 09.37 W. Schrader GERMANY Case report: severe rupture caused by the fork of a fork lift truck - whether and when to give up reconstruction 09.44 T. Imshanetskaya BELARUS Case report: combined Ahmed valve implantation and removal of dislocated  lens for treatment of traumatic glaucoma after ocular contusion 09.51 C. Forlini ITALY, A. Nikolakopoulos GREECE Discussion conclusion 10.00 End of course
  33. 33. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 31 11.00 – 12.30 FREE PAPER SESSION 5 Vascular Diseases and Diabetic Retinopathy II Venue: Boulevard C (Level 1) Chairpersons: T. Avitabile ITALY R. Tadayoni FRANCE 11.00 K. Sousa, C. Ferreira, L. Mendonça, R. Gentil, R. Leite, F. Vaz, N. Gomes PORTUGAL Efficacy of micropulse 532 NM green laser in diabetic macular edema 11.08 V. Yarmak, T. Imshenetskaya, G. Vashkevich, I. Malinovskaya BELARUS Clinical characteristics of endophthalmitis after intravitreal injection of antivascular endothelial growth factor agent 11.16 T. Sujirakul, D. Rojanaporn, P. Preechawat, P. Hanutsaha, C. Chen, A. Orlin, L. Yannuzzi USA Retrograde ocular arterial occlusions after subcutaneous filler injections 11.24 M. Abdul Karim, R. Singh, P. Ashwin UK Sustained topical anaesthesia for intravitreal implantation surgery 11.32 P. Volodin, I. Iablokova, A. Borisova RUSSIA Optimized technique of pattern laser photocoagulation for active retinopathy of prematurity 11.40 V. Dzinic, M. Dzinic, A. Oros SERBIA Central macular thickness (CMT) changes after phacoemulsification in patients with previously treated diabetic retinopathy (DR) and diabetic macular edema (DME) 11.48 J. Kirk, R. Healy, P. Scanlon, R. Johnston, Q. Mohamed UK Change in glycosylated haemoglobin in patients with centre involving diabetic macular edema treated with intravitreal ranibizumab 11.56 F. Manurung, G. Adriono INDONESIA Intravitreal bevacizumab therapy for treatment of retinopathy of prematurity- experience in Jakarta eye center, Indonesia 12.04 R. Narayanan, B. Panchal, J. Chhablani, T. Das, S. Jalali, R. Pappuru INDIA A randomized, double masked, controlled study of the efficacy and safety of intravitreal ranibizumab versus bevacizumab in subjects with macular edema secondary to branch retinal vein occlusion 12.12 T. Papathomas, L. Makris, A. Kamal UK 1 year follow-up of dexamethasone intravitreal implant (Ozurdex® ) in macular edema due to retinal vein occlusions 12.20 P. Prakash, D. Hanumunthadu, S. Arghandawi UK Efficacy of intravitreal dexamethasone implants for macular edema secondary to retinal vein occlusion - in day to day NHS practice 12.30 End of session 11.00 – 12.30 FREE PAPER SESSION 6 Imaging I Venue: Boulevard D (Level 1) Chairpersons: G. Coscas FRANCE C.H. Meyer GERMANY 11.00 T. Alabduljalil, C. Toth, A. Reginald, C. Westall, S. Farsiu, A. Arshavsky, W. Lam CANADA Demonstration of anatomical development of the human macula within the first five years of life using bioptigen optical coherence tomography (OCT) 11.08 K. Eibenberger, B. Gerendas, P. Roberts, W. Bühl, M. Kundi, U. Schmidt-Erfurth, S. Sacu AUSTRIA Prediction of recurrent central serous chorioretinopathy at initial examination 11.16 J. Ruiz-Medrano, I. Flores-Moreno, P. Peña-García, J. Montero, J. Duker SPAIN Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography 11.24 A. Arora, E. Pavlidou, K. Kopsidas, V. Papastefanou, V. Cohen, M. Sagoo UK Variability of choroidal thickness measurements in choroidal nevi using enhanced depth optical coherence tomography 11.32 U. Schraermeyer GERMANY Foveolar cones and müller cells of monkeys and humans have a unique, still unknown morphology with impact for understanding the Stiles-Crawford effect 11.40 A. Ferrero, A. Bonnabel, L. Gascard, A. Bron, C. Creuzot-Garcher FRANCE 1 year results of the follow-up of patients with asymptomatic idiopathic epiretinal membrane 11.48 M. Abouhussein, A. Gomaa EGYPT OCT findings in high myopia 11.56 T. Burke, T. Duncker, R. Woods, R. Smith, R. Allikmets, J. Sparrow, F. Delori USA Quantitative fundus autofluorescence in recessive Stargardt disease 12.04 T. Duncker, S. Tsang, W. Lee, J. Zernant, R. Allikmets, F. Delori, J. Sparrow USA Quantitative fundus autofluorescence and optical coherence tomography in bull’s-eye maculopathy 12.12 D. Odrobina, P. Gozdek, M. Maroszyński, I. Laudańska-Olszewska POLAND Subfoveal choroidal thickness after scleral buckling surgery with and without encircling band for macula-off rhegmatogenous retinal detachment in long-term observations 12.24 K. Spiteri Cornish, J. Ho, S. Downes, N. Lois UK The epidemiology of Stargardt disease 12.30 End of session
  34. 34. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER32 11.00 – 12.30 INSTRUCTIONAL COURSE 11 Laser Therapy in Retinal Disease: Indications Procedures Boulevard H (Level 1) Course Organisers: T. Lai HONG KONG A. Loewenstein ISRAEL E. Midena ITALY Cost: €25 11.00 F. Bandello ITALY PRP for PDR 11.12 C. Pournaras SWITZERLAND Mechanisms of laser treatment and its influence on blood retina barrier 11.24 T. Lai HONG KONG PDT: is it still relevant? 11.36 A. Augustin GERMANY Laser for vein occlusion 11.48 E. Midena ITALY Laser for DME, including subthreshold 12.00 R. Siegel ISRAEL Laser for ROP 12.12 M. Goldstein ISRAEL Case studies and discussion 12.24 Discussion 12.30 End of course 11.00 – 12.30 INSTRUCTIONAL COURSE 10 State-of-the-Art in Anti-VEGF Therapy Boulevard E (Level 1) Course Organiser: U. Schmidt-Erfurth AUSTRIA Cost: €25 11.00 U. Schraermeyer GERMANY What are the differences between anti-VEGF substances? 11.13 U. Schmidt-Erfurth AUSTRIA What works best in neovascular AMD? 11.26 A. Loewenstein ISRAEL When and why to switch from one substance to another? 11.39 M. Larsen DENMARK How much anti-VEGF is needed in DME? 11.52 F. Bandello ITALY Is anti-VEGF the only option in RVO? 12.05 A. Klettner GERMANY Is the discussion about safety over? 12.18 Discussion 12.30 End of course
  35. 35. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 33 11.00 – 12.30 INSTRUCTIONAL COURSE 12 Pearls Pitfalls in the Imaging of the Posterior Fundus Boulevard G (Level 1) Course Organiser: U. Chakravarthy UK Cost: €25 11.00 R. Danis USA Interpreting multicolor imaging 11.15 G. Staurenghi ITALY Misuse and misinterpretation of indocyanine green angiography 11.30 G. Soubrane FRANCE Misuse and misinterpretation of optical coherence tomography 11.45 P. Praveen UK Automated segmentation misuse and misinterpretation in OCT 12.00 S. Sadda USA Misuse and misinterpretation of autofluorescence 12.15 Discussion 12.30 End of course 11.00 – 12.30 INSTRUCTIONAL COURSE 13 Macular Dystrophies Boulevard I (Level 1) Course Organisers: G. Querques ITALY E. Souied FRANCE Cost: €25 11.00 G. Querques ITALY Best disease 11.15 C. Boon THE NETHERLANDS Pattern dystrophies 11.30 E. Souied FRANCE Stargardt disease and FFM 11.45 C. Hoyng THE NETHERLANDS Macular dystrophies mimicking AMD 12.00 B. Leroy BELGIUM Cone dysfunction syndromes 12.15 I. Audo FRANCE X-linked retinoschisis 12.30 End of course
  36. 36. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER34 14.00 – 16.00 MAIN SESSION 4 The Eye The Brain Auditorium (Level 0) Chairpersons: D. Palanker USA G. Richard GERMANY 14.00 S. Schippling SWITZERLAND OCT in demyelinating disease of the CNS – is the retina a ‘mini brain’? 14.18 B. Stemplewitz GERMANY Neuroimaging in Parkinson`s disease – does OCT help us? 14.36 A. Augustin GERMANY SD-OCT imaging of nerve fiber layer 14.54 S. Rizzo ITALY Update on the Argus II Retinal Prosthesis System 15.12 D. Palanker USA Restoration of sight with high resolution photovoltaic subretinal prosthesis 15.30 G. Richard GERMANY Limitations of retinal prosthesis 15.48 Discussion 16.00 End of session 12.00 – 13.00 Amsterdam Retina Debate Auditorium (Level 0) Chairperson: S. Lesnik-Oberstein THE NETHERLANDS Debate 1: Surgery Still Has a Role in AMD For: M. Mura THE NETHERLANDS Against: F. Holz GERMANY Debate 2: Floaterectomy is Justified For: C. Toth USA Against: A. Laidlaw UK
  37. 37. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 35 14.30 – 16.00 EVICR.net Session - Clinical Trial Research Boulevard D (Level 1) Chairperson: J. Cunha-Vaz PORTUGAL 14.30 J. Cunha-Vaz PORTUGAL EVICR.net status. Ongoing network research in retinal diseases 14.40 A. Tufail UK Need for validation of endpoints for retinal diseases 14.50 L. Ribeiro PORTUGAL Identifying NPDR progressors - RET-02 clinical trial 15.00 S. Harding UK EUROCONDOR clinical trial – neuroprotection for non-proliferative diabetic retinopathy 15.10 J. Figueira PORTUGAL PROTEUS clinical trial – anti-VEGF role in proliferative diabetic retinopathy 15.20 F. Holz GERMANY Emerging innovative treatments for dry AMD 15.30 Round-Table: EVICR.net role in investigator-driven clinical research and collaborations with industry - F. Bandello ITALY - J. Cunha-Vaz PORTUGAL - F. Holz GERMANY - A. Tufail UK - S. Harding UK - I. Kulyk SWITZERLAND - G. Norrgren SWEDEN 16.00 End of symposium 14.30 – 16.00 FREE PAPER SESSION 7 Vitreoretinal Surgery II Venue: Boulevard C (Level 1) Chairpersons: S. Schmitz-Valckenberg GERMANY T. Wolfensberger SWITZERLAND 14.30 S. Dsouza, N. Kumar, R. Battu, A. Braganza, D. Das, V. Kharbanda, R. Shetty INDIA The efficacy of 0.75% levobupivacaine versus 0.75% ropivacaine with fentanyl for peribulbar anesthesia in vitreoretinal surgery 14.38 S. Batta Arora, S. Batta, N. Goel, G. Bhushan, S. Thirumalai, A. Seth, M. Thakar INDIA Comparative evaluation of brilliant blue staining using whole blood versus conventional brilliant blue staining for internal limiting membrane peeling in macular hole surgery 14.46 L. Scheerlinck, P. Schellekens, D. Steijns, A. Liem, R. van Leeuwen THE NETHERLANDS Unexplained visual acuity after intraocular silicone oil 14.54 N. Gomes, K. Sousa, S. Guimarães, L. Mendonça, R. Gentil, R. Leite, J. Mendes PORTUGAL Internal limiting membrane peeling in macula-off retinal detachment 15.02 A. Ramezani, H. Ahmadieh, A. Rozegar, M. Soheilian, M. Entezari, S. Moradian, H. Nikkhah IRAN Predictors and outcomes of vitrectomy plus silicone oil injection in eyes with complex diabetic retinopathy 15.10 N. Kannan, K. Arumugam, K. Ramasamy INDIA 2cc 100% SF6 as tamponading agent in macular hole surgery 15.18 T. Papathomas, S. Murjaneh UK Dilated pupil after vitrectomy and argon laser treatment 15.26 M. Elmalt EGYPT Fashioned retinotomy for management of recurrent lower retinal detachment with inferior proliferative vitreo- retinopathy 15.34 P. Susvar, C. Rao, A. Maheshwari INDIA Vitreoretinal perspective of scleral fixated intraocular lens – a case series 15.42 H. Yetik, S. Sirop, C. Dogan, M. Gunay TURKEY Post-vitrectomy macular holes-results of re-operation vitrectomy 15.50 K. Ghasemi Falavarjani, M. Modarres, M. Hashemi, M. Parvaresh, M. Naseripour, A. Karimi Moghaddam, A. Hadavand Khani IRAN Intra-silicone oil injection of methotrexate at the end of vitrectomy for retinal detachment associated with advanced proliferative diabetic retinopathy 16.00 End of session
  38. 38. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER36 14.30 – 16.00 INSTRUCTIONAL COURSE 14 Management of Proliferative Diabetic Retinopathy Boulevard H (Level 1) Course Organisers: A. Laidlaw UK M. Mohamed UK Cost: €25 14.30 A. Laidlaw UK Welcome and introduction 14.40 L. Downey UK Pathophysiology of PDR 14.50 S. Mann UK Epidemiology, classification and screening for PDR 15.00 M. Mohamed UK PRP, when to start, where to do it, how much to do, when to stop 15.10 S. Mann UK Addressing general medical risk factors 15.20 R. Wong UK Role of anti-VEGF drugs: current and future, anterior hyaloid proliferation and rubeosis 15.30 T. Williamson UK Diabetic vitreous haemorrhage: aetiology and management 15.40 D. Steel UK Retinal traction from PDR: aetiology and management 15.50 Discussion 16.00 End of course 14.30 – 16.00 BIO-ENGINEERING SOCIETY SYMPOSIUM RETINATECH: Envisioning the Future of Vitreoretinal Surgery Boulevard E (Level 1) Chairpersons: Y. Oshima JAPAN T. Rossi ITALY D. Wong HONG KONG 14.30 T. Rossi ITALY Introduction 14.33 D. Wong HONG KONG Finite element analysis and surgery for high myopia 14.41 C.H. Meyer SWITZERLAND Geometry, penetration forces and cutting profile of different 23G trochar systems 14.49 S. Rizzo ITALY New technologies in vitreous cutter 14.57 C. Eckardt GERMANY The TDC-Cutter – high speed cutting in the fast lane 15.05 T. Rossi ITALY Constant flow vitrectomy/ The fluidics of infusion during pars plana vitrectomy 15.13 T. Hassan USA The continuing evolution of portable vitrectomy 15.21 T. Rossi ITALY Real time pressure monitoring during pars plana vitrectomy 15.29 M. Romano ITALY Temperature control: a new surgical tool 15.37 D. Chow CANADA Advances in endoillumination 15.45 K. Kojima, Y. Oshima JAPAN Supra-choroidal approach for retinal surgery: results from basic experiments 15.53 Conclusion 16.00 End of symposium
  39. 39. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 37 14.30 – 16.00 INSTRUCTIONAL COURSE 15 Key Issues for SD-OCT Interpretation Boulevard G (Level 1) Course Organisers: A. Gaudric FRANCE G. Staurenghi ITALY A. Tufail UK Cost: €25 14.30 A. Gianni ITALY, G. Staurenghi ITALY Basics of OCT interpretation, new nomenclature: Choroid in various diseases Retinal angiomatous proliferation 15.00 P. Keane UK, A. Tufail UK Age macular degeneration 15.30 A. Gaudric FRANCE, S. Mrejen USA Vitreo-macular diseases, macular edema 16.00 End of course 14.30 – 16.00 INSTRUCTIONAL COURSE 16 Uveitis – Diagnosis Therapy in 2014 Boulevard I (Level 1) Course Organisers: M. Funk AUSTRIA H. Kaplan USA Cost: €25 14.30 H. Kaplan USA New advances in diagnosis 14.48 M. Funk AUSTRIA New advances in imaging 15.06 U. Pleyer GERMANY Update on therapy 15.24 J. de Boer THE NETHERLANDS Update on pediatric uveitis 15.42 Discussion 16.00 End of course
  40. 40. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER38 16.00 – 18.00 MAIN SESSION 5 Neovascular AMD Auditorium (Level 0) Chairpersons: M. la Cour DENMARK S. Wolf SWITZERLAND 16.00 T.L. Sørensen DENMARK Systemic immunological changes in AMD. Are they relevant? 16.18 F. Holz GERMANY Long term results after anti-VEGF therapy in exudative AMD 16.36 K. Berg NORWAY LUCAS-Study 16.54 M. Zinkernagel SWITZERLAND Is zero tolerance necessary? 17.12 G. Staurenghi ITALY Eye drops for the treatment of neovascular age-related macular degeneration 17.30 S. Harding UK Treatment of exudative AMD: Mechanism beyond VEGF 17.48 R. Johnston UK Neovascular age-related macular degeneration (nAMD): visual outcomes of treatment naïve eyes with baseline visual acuity better than 70 ETDRS letters 17.56 Closing comments 18.00 End of session 16.30 – 18.00 FREE PAPER SESSION 8 Imaging II Venue: Boulevard C (Level 1) Chairpersons: A. Gaudric FRANCE G. Soubrane FRANCE 16.30 C. Kucukerdonmez, M. Zengin, S. Yılmaz, E. Cinar TURKEY Choroidal thickness changes during growth- a cross- sectional study in participants aged between 4-23 years 16.38 P. Aristodemou, N. Kumar, S. Murjaneh, M. Brelen, M. Majid, R. Haynes, A. Dick CYPRUS The reliability of OCT in detecting attached posterior vitreous before surgery for macular holes and epiretinal membranes 16.46 D. Mitry, T. Peto, J. Morgan, P. Foster UK Crowdsourcing as a novel technique for retinal fundus photography classification 16.54 L. Berger, C. Dysly, J. Kowal, S. Wolf, M. Zinkernagel SWITZERLAND Fluorescence lifetime characteristics in central serous chorioretinopathy 17.02 S. Pastor-Idoate, M. Gil-Martinez, S. Charles, S. Biswas, D. Henson, D. McLeod, P. Stanga UK Swept-source optical coherence tomography assessment of the cortical vitreous and choroidal thickness in different macular disorders 17.10 O. Fleck, P. Koehrer, S. Vinault, C. Tzourio, A. Bron, C. Binquet, C. Creuzot-Garcher FRANCE Macular thickness in a French population over 75 years old (Montrachet’s study- maculopathy, optic nerve, nutrition, neurovascular and heart diseases) 17.18 C. Mitsch, R. Leitgeb, U. Schmidt-Erfurth AUSTRIA Non-invasive retinal and choroidal microangiography using 1060nm dual-beam doppler optical coherence tomography in patients with choroidal neovascularization, proliferative diabetic retinopathy and branch retinal vein occlusion 17.26 S. Patwary, S. Winder UK Virtual clinics using ultra-widefield retinal photography in patients with posterior vitreous detachment 17.34 U. Kayabasi, R. Sergott TURKEY Retina examination with examination with curcumin for the diagnosis of Alzheimer’s disease 17.42 A. Abdullatif, H. Mortada, M. Abdelhakim, H. El Said EGYPT Structure-function relationship following primary vitrectomy for rhegmatogenous retinal detachment of intermediate severity 18.00 End of session
  41. 41. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 39 16.30 – 18.00 ASRS SYMPOSIUM Retina in the Future: Where Are We Headed? Boulevard E (Level 1) Chairpersons: T. Hassan USA P. Kaiser USA 16.30 T. Hassan USA The state-of-the-art in vitreous cutters – now and in the future 16.41 D. Chow CANADA Intraoperative light: the continued evolution 16.52 P. Ferrone USA Surgical visualization: what can we see now and what will we see in the future? 17.03 S. Schwartz USA Stem cell therapy for retinal disease 17.14 S. Rizzo ITALY Artificial vision: what will the future hold? 17.25 P. Kaiser USA The future of AMD therapy 17.36 P. Dugel USA Neuroprotection of the retina: now and in the future 17.47 C. Gonzales USA A novel therapy targeting tissue factor for the treatment of neovascular AMD 18.00 End of symposium 16.30 – 18.00 FREE PAPER SESSION 9 Vascular Diseases and Diabetic Retinopathy III Venue: Boulevard D (Level 1) Chairpersons: B. Leroy FRANCE J. van Meurs THE NETHERLANDS 16.30 A. Loewenstein, E. Moisseiev ISRAEL A collaborative retrospective trial on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema (ARTES study) 16.38 R. Eltanamly, R. Abdelfattah, M. Nabih, M. Kamal EGYPT Association of VEGF gene polymorphism rs699947 and rs10434 with diabetic retinopathy in Egyptian patients 16.46 Y. Dong, M. Elgohary, M. Syrimi, V. Sivagnanavel UK Intravitreal dexamethasone implant in retinal vein occlusion - clinical outcome using as-required repeat injection regimen 16.54 A. Awadein, M. El-Shazly EGYPT Diabetic neurosensory serous detachment of the fovea- patient characteristics and response to intravitreal ranibizumab 17.02 S. Malhotra, D. Agarwal, S. Chatterjee, A. Sahu, I. Nanda INDIA Visual outcome and central macular thickness after phacoemulsification with intravitreal bevacizumab in patients with diabetic macular edema and cataract 17.10 S. Sizmaz, E. Esen, A. Sariyeva, N. Demircan TURKEY Laser photocoagulation in retinopathy of prematurity and prognostic factors 17.18 S. Nicoara, C. Nascutzy, C. Cristian, I. Irimescu, A. Stefanut, G. Zaharie ROMANIA Avastin monotherapy in severe retinopathy of prematurity - outcomes and prognostic factors 17.26 T. Pilkevich, N. Pasyechnikova, V. Naumenko, V. Vit, E. Ivanitskaya UKRAINE Peculiarities of structural changes of the retina in streptozotocin-induced diabetic rats in different terms (2 weeks and 1 month) 17.34 Y. Cho, M. Kim, H. Koh SOUTH KOREA Changes in visual acuity, central foveal thickness and choroidal thickness in refractory diabetic macular edema after intravitreal dexamethasone implant 17.42 M. Kaya, S. Kaynak, D. Er, T. Ozturk, N. Kocak TURKEY Evaluation on intraretinal hyperreflective foci density with SD-OCT after Ozurdex application in patients with diabetic macular edema 17.50 N. Feltgen GERMANY Impact of baseline perfusion status on visual outcomes in patients with macular edema secondary to central retinal vein occlusion (CRVO) treated with intravitreal aflibercept (IVT-AFL)- data from the COPERNICUS and GALILEO studies 18.00 End of session
  42. 42. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER40 16.30 – 18.00 INSTRUCTIONAL COURSE 17 Update in Ocular Oncology 2014 Boulevard H (Level 1) Course Organiser: A. Joussen GERMANY Cost: €25 16.30 A. Riechardt GERMANY Are OCT, FAG and autofluorecense sufficient for differential diagnosis of small choroidal lesions? 16.42 H. Heimann GERMANY Cyberknife, binuclid radioactive plaques or proton beam? 16.54 M. Rehak GERMANY Should every lesion be biopsied? 17.06 N. Bechrakis AUSTRIA Surgery after irradiation of large ocular tumours – a necessity or possible alternatives? 17.18 S. Leyvraz SWITZERLAND Help in sight for metastatic choroidal melanoma? 17.30 I. Seibel GERMANY, S. Erzkuraj GERMANY Choroidal metastesis – sight of the clinician and the pathologist 17.42 A. Joussen GERMANY Vascular tumours and vascular abnormalities – treatment challenges 17.54 Discussion 18.00 End of course 16.30 – 18.00 INSTRUCTIONAL COURSE 18 Subthreshold Laser Surgery Boulevard G (Level 1) Course Organisers: C. Boon THE NETHERLANDS V. Chong UK J. Keunen THE NETHERLANDS E. Midena ITALY Cost: €25 16.30 J. Keunen THE NETHERLANDS Recent developments in subthreshold laser surgery 16.45 V. Chong UK Basic principles of micropulse laser and differences to other subthreshold laser techniques 17.00 E. Midena ITALY Subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation in DME 17.15 J. Luttrull USA Safety of transfoveal subthreshold diode micropulse laser for DME in eyes with good visual acuity 17.30 C. Boon THE NETHERLANDS The PLACE trial: subthreshold micropulse laser treatment versus PDT in chronic central serous chorioretinopathy 17.45 Discusssion 18.00 End of course
  43. 43. LONDON14th EURETINA Congress FRIDAY 12 SEPTEMBER 41 16.30 – 18.00 INSTRUCTIONAL COURSE 19 Update in OCT Imaging: Indications, Features, Consequences Boulevard I (Level 1) Course Organiser: U. Schmidt-Erfurth AUSTRIA Cost: €25 16.30 C. Simader AUSTRIA A long list of OCT deficiencies 16.43 U. Schmidt-Erfurth AUSTRIA Novel OCT concepts in early and late AMD 16.56 G. Staurenghi ITALY An updated role of OCT in DME 17.09 A. Lotery UK OCT features in retinal dystrophies 17.22 C. Toth USA Hallmarks of progression from early to intermediate to advanced AMD by OCT 17.35 M. Pircher AUSTRIA Advances in adaptive optics (AO) imaging 17.48 Discussion 18.00 End of course
  44. 44. EURETINA Winter Meeting Saturday 24 January 2015 5th University of Oxford, UK www.euretina.org
  45. 45. SATURDAY13 September LONDON14th EURETINA Congress 43
  46. 46. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER44 08.00 – 10.00 MAIN SESSION 6 Uveal Melanoma: Current Conflicts Controversies Auditorium (Level 0) Chairpersons: D.E. Pelayes ARGENTINA S. Seregard SWEDEN 08.00 M. Jager THE NETHERLANDS What makes uveal melanoma special 08.15 J. García Arumí SPAIN Why primary endoresection is harmless 08.30 N. Bornfeld GERMANY Why primary endoresection is harmful 08.45 L. Zografos SWITZERLAND Tumours are best treated with protons 09.00 S. Seregard SWEDEN Tumours are best treated with plaques 09.15 T. Kivelä FINLAND Screening for metastases is useful 09.30 D. Gombos USA Screening for metastases is useless 09.45 Discussion 10.00 End of Session 08.00 – 09.30 THE CLUB JULES GONIN SYMPOSIUM Minimal and Maximal Surgery: What is Sufficient, What is Necessary? Boulevard C (Level 1) Chairpersons: B. Aylward UK F. Bandello ITALY Y. Le Mer FRANCE 08.00 J. van Meurs THE NETHERLANDS RPE-choroid transplantation: an alternative when there is nothing left to do 08.10 C. Claes BELGIUM 27G vitrectomy: gadget or future of surgery? 08.20 P. Szurman GERMANY Corneal keratoprosthesis and vitrectomy in severely traumatised eyes 08.30 T. Wolfensberger SWITZERLAND Some euros to save the cornea 08.40 D. Charteris UK Retinal detachment complicated with severe PVR: when to stop? 08.50 A. Laidlaw UK Do we still need positioning after MH surgery? 09.00 F. Bandello ITALY, R. Tadayoni FRANCE Submacular hemorrhages in AMD: we don't need vitrectomy/we need vitrectomy to save vision 09.20 Discussion 09.30 End of symposium
  47. 47. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 45 08.00 – 09.30 ASIA PACIFIC VITREORETINAL SOCIETY SYMPOSIUM (APVRS) Maculopathy in the Asian Population Boulevard D (Level 1) Chairpersons: A. Chang AUSTRALIA T. Lai HONG KONG M. Ohji JAPAN 08.00 T. Iida JAPAN Imaging techniques of polypoidal vasculopathy 08.11 X. Li CHINA Two approaches to treat polypoidal vasculopathy 08.22 G. Kokame HAWAII, USA The role of anti-VEGF in treatment of polypoidal vasculopathy 08.33 G. Cheung SINGAPORE Epidemiology of myopia in Asia 08.44 T. Lai HONG KONG Management options in myopic choroidal neovascularisation 08.55 Y. Ikuno JAPAN Pathogenesis of myopic foveoschisis 09.06 M. Ohji JAPAN Surgical treatments for foveoschisis and macular hole retinal detachment 09.17 A. Chang AUSTRALIA Complications and pitfalls in the surgery of myopic maculopathy 09.28 Discussion 09.30 End of symposium 08.00 – 10.00 FREE PAPER SESSION 10 Vitreoretinal Surgery III Venue: Boulevard E (Level 1) Chairpersons: F. Arevalo SAUDI ARABIA S. Binder AUSTRIA 08.00 P. Stavrakas, A. Vakalis, S. Asteriadis, E. Lokovitis, P. Tranos GREECE Persistent subretinal fluid after successful full thickness macular hole surgery - prognostic factors, morphological features and implications on functional recovery 08.08 R. Singh, R. Samanta, M. Dogra, A. Gupta INDIA 23-gauge transconjunctival sutureless vitrectomy versus 20-gauge vitrectomy with scleral buckling in pseudophakic rhegmatogenous retinal detachment 08.16 C. Gupta, C. Shroff, P. Gupta, D. Shroff, N. Atri INDIA Comparison of three different formulations of brilliant blue G dye with indocyanine green dye and trypan blue dye for ILM staining in macular hole surgery 08.24 M. Elgohary, P. Pongsachareonnont, R. Muni, W. Lam, P. Kertes, A. Ali UK Outcome of surgical excision and histopathologcial features of cyclitc membranes in children 08.32 N. Ferreira, C. Vale, T. Coelho PORTUGAL Late onset familial amyloid polyneuropathy (FAP) ocular manifestations in Portuguese patients 08.40 A. Kaintatzis, R. Johnston, N. Kirkpatrick, A. Sallam UK Risk of retinal detachment following complicated and uncomplicated cataract surgery- a review of 30,188 consecutive cataract operations 08.48 M. El-Ashry, H. Rehman, H. Goh, N. Gunn, A. Babar, M. Costen, N. UK Vitrectomy for floaters in the national health service (NHS)- fiction or fact 08.56 T. Rossi, G. Querzoli, C. Malvasi, A. Rossi, G. Angelini ITALY Continuous real-time pressure monitoring during pars plana vitrectomy 09.04 J. Park, B. Ramasamy, S. Shaw, S. Prasad, R. Ling UK A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy 09.12 S. Saw SINGAPORE Myopia-related fundus changes in Singaporean adults with high myopia 09.20 S. Sheta EGYPT Vitrectomy for the management of diabetic vitreo macular traction with impending macular hole 09.28 I. Dooley, H. Laviers, H. Zambarakji UK Is cystoid macular edema more frequent in vitrectomised internal limiting membrane-peeled eyes undergoing phacoemulsification?
  48. 48. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER46 08.00 – 09.30 YOUNG EUROPEAN RETINA SPECIALISTS SYMPOSIUM (YOURETINA) Frontiers in Retinal Therapy: Revelations and Revolutions Boulevard H (Level 1) Chairpersons: C. Boon THE NETHERLANDS M. Fleckenstein GERMANY G. Querques FRANCE 08.00 D. Fischer UK Gene therapy – coming to your clinic soon? 08.15 R. Gallego-Pinazo SPAIN Age-related macular degeneration – time for personalized medicine? 08.30 S. Mrejen USA Impact of different AMD phenotypes on cone density 08.45 M. Rehak GERMANY Do we really need modern retinal imaging in patients with retinal vein occlusion? 09.00 J. Dolar-Szczasny POLAND Ultra-widefield imaging – clinical revolution? 09.15 M. Romano ITALY Surgical treatment of non-tractional diabetic macular edema: does it make sense? 09.30 End of symposium 09.36 T. Sinha, S. Boral INDIA Sub silicon oil triamcinolone(TA) drop - a new simple approach to prevent post operative proliferative vitreoretinopathy (PVR) 09.44 A. Papayannis, D. Bonsanto, P. Iacono, M. Battaglia Parodi, F. Foltran, G. Prosdocimo, F. Bandello ITALY Multimodal imaging of sticky oil phenomenon in eyes with rhegmatogenous retinal detachment treated with vitrectomy and gas or silicone oil tamponade 10.00 End of session
  49. 49. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 47 08.00 – 09.30 INSTRUCTIONAL COURSE 20 The Intraocular Mirror Telescope: An Additive Treatment for AMD Eyes A Practical Course on Patient Selection, Surgical Technique Clinical Results Boulevard G (Level 1) Course Organisers: I. Lipshitz ISRAEL A. Loewenstein ISRAEL Cost: €25 08.00 I. Lipshitz ISRAEL Introduction; advantages of implanted telescopes 08.10 A. Loewenstein ISRAEL Review of available intraocular telescopes for AMD 08.20 I. Lipshitz ISRAEL Concept and design: description, specification, performance 08.30 A. Loewenstein ISRAEL Patient selection, education and examination 08.40 I. Lipshitz ISRAEL OptoLight Vision Testing program (OVT) 08.50 A. Agarwal INDIA Clinical and surgical experience 09.00 A. Loewenstein ISRAEL Clinical experience 09.10 I. Lipshitz ISRAEL Future of mirror implanted products 09.20 Discussion 09.30 End of course 08.00 – 09.30 INSTRUCTIONAL COURSE 21 Submacular Haemorrhages in AMD: A Practical Course on Optimum Management Boulevard I (Level 1) Course Organiser: D. Steel UK Cost: €25 08.00 D. Steel UK Introduction 08.12 Speaker TBC Epidemiology, mechanisms of visual loss, risk factors and classfn 08.24 Z. Koshy UK Clinical assessment: How to decide what to do – observation, anti VEGFs alone or surgery? 08.36 J. van Meurs THE NETHERLANDS Pneumatic displacement – how to do it 08.48 J. Hillenkamp GERMANY Vitrectomy and subretinal TPA/anti VEGF – how to do it 09.00 D. Yorston UK Results, complications and limitations – how do the two techniques compare? 09.12 D. Steel UK Too big to displace? What else can be tried 09.24 Discussion 09.30 End of course
  50. 50. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER48 11.00 – 13.00 EURETINA Science Medicine Innovation Award 2014 Auditorium (Level 0) Chairpersons: E. Stefánsson ICELAND S. Wolf SWITZERLAND The EURETINA Science Medicine Innovation Award is an initiative founded in 2011 with the purpose of supporting and encouraging innovation in the field of retinal science and medicine. All applications received have been reviewed by a panel of experts, from which six applicants are shortlisted to present their work at the 2014 Innovation Award Session. First and second place trophies are awarded at the end of the session. 11.00 – 12.30 EVER Functional and Morphological Imaging of the Ocular Fundus Boulevard C (Level 1) Chairpersons: G. Holder UK C. Pournaras SWITZERLAND 11.00 L. Zografos SWITZERLAND Wide view 150° ICG and FA in ocular oncology 11.11 V. Vaclavik SWITZERLAND Wide view auto-fluorescence in retinal dystrophies 11.22 C. Pournaras SWITZERLAND OCT imaging of the vitreoretinal interface 11.33 L. El Matri TUNISIA Evaluation of choroidal thickness in macular pathologies 11.44 L. Schmetterer AUSTRIA Functional OCT 11.55 G. Holder UK Electrophysiological evaluation in the investigation of inherited retinal disease 12.06 E. Stefánsson ICELAND Retinal oximetry on the evaluation of retinal metabolism 12.17 Discussion 12.30 End of symposium
  51. 51. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 49 11.00 – 12.30 FAN CLUB Retinal Imaging Cases for Discussion with a Panel Boulevard D (Level 1) Chairpersons: V. Chong UK A. Leys BELGIUM M. van Schooneveld THE NETHERLANDS Each case presentation lasts for ten minutes with five minutes for discussion. This symposium is open to all to attend. 11.00 – 13.00 FREE PAPER SESSION 11 Miscellaneous Venue: Boulevard E (Level 1) Chairpersons: G. Richard GERMANY T. Rossi ITALY 11.00 N. Vilà, P. Zoroquiain, V. Bravo-Filho, P. Logan, M. Burnier CANADA Primary intraocular and central nervous system lymphomas- are they the same? 11.08 A. Filloy Rius, S. Jordan, J. Caminal SPAIN Swept-source optical coherence tomography imaging of choroidal tumors 11.16 P. Kaiser, Y. Ito, S. Srivistava, J. Ehlers USA Clinical experience with ocriplasmin for the treatment of vitreomacular traction and macular hole - a single-centre case series 11.24 P. Lanzetta ITALY The time-course and resolution of key adverse events in the ocriplasmin clinical trial programme 11.32 L. Arias, M. López-Gálvez, M. Roura, M. Balaña SPAIN A phase II clinical trial to compare the efficacy and safety of ranibizumab versus laser photocoagulation in patients with visual impairment due to diabetic macular edema- the RE-DES study 11.40 E. Krüger, F. Holz, T. Heeren, T. Clemons, H. Scholl, A. Bird, P. Charbel Issa GERMANY Progression of functional loss in macular telangiectasia type 2 11.48 P. Jain, M. Thakar, U. Kaul Raina, B. Ghosh, G. Bhushan INDIA Comparative evaluation of conventional (pars plana vitrectomy) versus intravitreal bevacizumab assisted treatment for non-resolving vitreous hemorrhage (NRVH) in Eales’ disease 11.56 S. Das, R. Roy, S. Pal INDIA Microbiological trends and drug sensitivity patterns in endophthalmitis in Eastern India 12.04 M. Hosny, N. Khalil, R. Abdel Salam EGYPT Changes in retinal nerve fiber layer thickness following mechanical microkeratome-assisted versus femtosecond- assisted LASIK 12.12 S. Parikh, R. Jain, S. Malli INDIA Comparison of conventional scleral fixation versus modified trans scleral fixation of intra ocular lens during combined vitreoretinal surgery 12.20 M. Barman, H. Bhattacharjee, S. Deka, D. Das INDIA Intraocular helminthic infestation-presentation and management 12.28 S. Binder, C. Falkner-Radler, F. Zeiler, C. Ginzel, C. Glittenberg AUSTRIA Intraoperative continuous OCT- the rescan 700
  52. 52. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER50 11.00 – 12.30 INSTRUCTIONAL COURSE 22 Managing Diabetic Macular Edema: Pearls and Pitfalls Boulevard H (Level 1) Course Organisers: A. Joussen GERMANY E. Midena ITALY Cost: €25 11.00 A. Joussen GERMANY Diabetic macular edema (DME): a multifactorial entity 11.15 T. Peto UK Detecting DME: the screening approach 11.30 S. Vujosevic ITALY DME multimodal imaging: diagnostic and prognostic implications 11.45 E. Midena ITALY DME treatment: a tailored approach 12.00 M. Bolz AUSTRIA Vitreoretinal surgery in DME: early approach vs last chance 12.15 Discussion 12.30 End of course 12.36 T. Painhas, M. Ruão, R. Soares, C. Manso, A. Gomes da Rocha, J. Chibante-Pedro PORTUGAL Pneumatic retinopexy in the treatment of rhegmatogenous retinal detachment- our experience 12.44 G. Pardianto INDONESIA Impact of intraocular pressure fluctuation in cataract surgery to specific area and volume of the macula 12.52 Q. Nguyen, L. Wilson, J. Naor, W. Liu, M. Valentine, N. Shams USA Baseline characteristics of SAKURA- a phase III, multicenter, randomized, double-masked study of intravitreal injections of DE-109 for the treatment of active, non-infectious uveitis of the posterior segment 13.00 End of session
  53. 53. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 51 11.00 – 12.30 INSTRUCTIONAL COURSE 24 Steroids in Retinal Therapy Boulevard I (Level 1) Course Organiser: A. Augustin GERMANY Cost: €25 11.00 B. Kuppermann USA Steroids for the treatment of retinal diseases: basic research and devices 11.15 F. Boscia ITALY Steroids for the treatment of DME 11.30 A. Loewenstein ISRAEL Steroids for the treatment of uveitis and other vascular diseases 11.45 S. Rizzo ITALY Steroid as an important adjunct before, during and after vitreoretinal surgery 12.00 A. Augustin GERMANY Combination of steroids with drugs and/or laser for the treatment of macular edema 12.15 Discussion 12.30 End of course 11.00 – 12.30 INSTRUCTIONAL COURSE 23 Vitreoretinal Interface Boulevard G (Level 1) Course Organiser: D.E. Pelayes ARGENTINA Cost: €25 11.00 D.E. Pelayes ARGENTINA New OCT technology in VRIF. Retinal digital biopsy 11.09 A. Nikolakopoulos GREECE Current pucker and traction macular surgery in VR interface. New techniques using wide angle observation systems 11.18 A. Gaudric FRANCE Early vitreo-macular traction: Do we know the natural history? 11.27 T. Wolfensberger SWITZERLAND Pharmacological and surgical combination in vitreoretinal interface 11.36 R. Cano MEXICO Predictors of visual outcome in vitreo macular surgery 11.45 F. Graue MEXICO The importance of internal limiting membrane and external limiting membrane 11.54 M. Nehemy BRAZIL Surgical techniques for special cases of macular disease 12.03 B. Corcóstegui SPAIN Myopic hole interface 12.12 Y. Le Mer FRANCE Small macular holes: do we still need surgery? 12.21 D.E. Pelayes ARGENTINA Discussion 12.30 End of course
  54. 54. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER52 14.00 – 16.00 ESCRS/EURETINA JOINT SYMPOSIUM Vitreoretinal Complications of Anterior Segment Surgery Auditorium (Level 0) Chairpersons: F. Bandello ITALY R. Bellucci ITALY 14.00 O. Findl AUSTRIA The broken capsule and the vitreous 14.15 M. la Cour DENMARK Pseudophakia and retinal detachment 14.30 Discussion 14.40 R. Nuijts THE NETHERLANDS Cystoid macular edema 14.55 G. Richard GERMANY Choroidal detachment after anterior segment surgery 15.10 Discussion 15.20 S. Wolf SWITZERLAND How to handle a dropped nucleus 15.35 U. Schmidt-Erfurth AUSTRIA The retina after anti-VEGF injections at the time of cataract surgery 15.50 Discussion 16.00 End of symposium 14.30 – 16.30 FREE PAPER SESSION 12 New Drug Treatment Venue: Boulevard F (Level 1) Chairpersons: B. Kuppermann USA Y. Le Mer FRANCE 14.30 J-F. Korobelnik FRANCE The MYRROR study - detailed evaluation of visual outcomes following intravitreal aflibercept injection in patients with choroidal neovascularisation secondary to pathological myopia 14.38 L. Ceklic, U. Wolf-Schnurrbusch, S. Wolf SWITZERLAND Visual acuity outcomes of ranibizumab vs verteporfirin photodynamic therapy (vPDT) treatment response in highly myopic eyes with dome shaped macular feature and choroidal neovascularisation 14.46 T. Wong SINGAPORE Prognostic factors associated with visual outcomes in patients receiving intravitreal aflibercept for choroidal neovascularisation secondary to pathological myopia- post hoc analyses from the MYRROR study 14.54 G. Cosendai, L. da Cruz, J. Sahel, P. Stanga, F. Hafezi, R. Greenberg, AII Study Group Switzerland Latest results from the Argus II retinal prosthesis system clinical trial 15.02 M. Arsiero, S. Rizzo, P. Walter, B. Kirchhof, A. Augustin, S. Grisanti, G. Richard SWITZERLAND European post-market surveillance study results for the Argus II retinal prosthesis system 15.10 C. Quijano, M. Gil-Martinez, S. Pastor-Idoate, S. Biswas, P. Stanga UK Anatomical and functional outcomes in x-linked retinoschisis treated with topical carbonic anhydrase inhibitor – dorzolamide 15.18 S. Hassan, M. Aboul Naga, M. Dithmer, M.M. Soliman, T.A. Macky, J. Roider, A. Klettner EGYPT Time-dependent intracellular pattern of bevacizumab uptake in RPE cells 15.26 A. Miranda, N. Marques, J. Cardoso, A. Cardoso, S. Barros, P. Telles, N. Campos PORTUGAL Evaluation of macular pigment optical density in patients treated with hydroxychloroquine 15.34 A. Machalińska, B. Machaliński, A. Józkowicz, J. Dulak POLAND Long-term neuroprotective effects of NT-4-engineered mesenchymal stem cells injected intravitreally in a mouse model of acute retinal injury 15.42 A. Aramburu del Boz, F. Díaz Corrales, B. de la Cerda Haynes, L. Valdés Sánchez, D. Rodriguez Martínez, S. Bhattacharya SPAIN Spatial vision and c-wave are affected in mouse models of human autosomal dominant retinitis pigmentosa caused by PRPF31 mutations
  55. 55. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 53 15.50 M. Gil, S. Pastor-Idoate, Y. D’Souza, S. Mahmood, C. Stephen, D. Henson, P. Stanga SPAIN Safe and effective barely visible and subthreshold endpoint treatment parameters for 577NM (yellow) Pascal® laser with and without endpoint management® in proliferative diabetic retinopathy and diabetic macular edema 15.58 T. Park, S. Lee, H. Kim, R. Brinkmann SOUTH KOREA Cellular response to selective retina therapy by microsecond-pulsed laser equipped with automated real- time reflectometry 16.06 A. Rajendran, T.P. Vignesh, K. Ramasamy INDIA A comparative analysis of the efficacy of subthreshold micropulse 577-nm yellow laser versus 577 nm green laser for central serous chorioretinopathy 16.14 A. Grzybowski, J. Pieczynski POLAND The role of antibiotics in the prevention of post-intravitreal anti-VEGF endophthalmitis - primum non nocere! 16.30 End of session 14.30 – 16.00 FREE PAPER SESSION 13 Imaging III Venue: Boulevard C (Level 1) Chairpersons: S. Sadda INDIA S. Seregard SWEDEN 14.30 R. Hua, L. Chen CHINA The progression rate of retinal pigment epithelium atrophy in punctate inner choroidopathy 14.38 P. Theodossiadis, G. Theodossiadis, V. Grigoropoulos, S. Theodoropoulou, I. Datseris GREECE Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography 14.46 A. Sharma, J. Sheth, RJ. Madhusudan, N. Vidhya, SK. Sundonamorthy, J. Patil INDIA Relationship of choroid and retinal thickness in high myopes using enhanced depth imaging optical coherence tomography 14.54 K. Gocho, S. Kameya, S. Kikuchi, K. Shinoda, A. Mizota, K. Yamaki, H. Takahashi JAPAN High-resolution adaptive optics images of microcystic macular edema in patients with autosomal dominant optic atrophy 15.02 S. Schmitz-Valckenberg, S. Liakopoulos, G. Spital, F. Ziemssen, A. Wiedon, F. Holz GERMANY ORCA – comparison of SD-OCT image analysis in real life compared to standardized reading center analysis 15.10 G. Yilmaz, N. Yesilirmak, S. Gur Gungor, E. Yaman Pinarci, I. Akkoyun TURKEY Enhanced depth imaging optical coherence tomography in patients with different phases of Behcet’s panuveitis 15.18 M. Gil, S. Pastor-Idoate, A. Jalil, J. Garcia-Vallejo, T. Ivannova, S. Charles, P. Stanga SPAIN Wide-field fundus autofluorescence and swept-source- optical coherence tomography imaging findings as predictor of visual outcome after successful retinal detachment surgery 15.26 I. Pires PORTUGAL Identifying progression of retinal disease in eyes with mild NPDR in diabetes type 2 using non-invasive procedures 15.34 A. Mohi, M. Ranjbar, H. Frenzel, S. Grisanti, M. Rudolf GERMANY First description of a melanoma-associated paraneoplastic syndrome with retinopathy and cochleopathy 15.42 V. Capuano, G. Querques, E. Cavallero, P. Frascio, E. Souied FRANCE Analysis of choroidal maps in non-exudative age- related macular degeneration using swept source optical coherence tomography 15.50 H. Almuhtaseb, J. Badal, M. Biarnés, J. Monés SPAIN Performance characteristics of multicolour versus blue light and infrared imaging in the identification of reticular pseudodrusen 16.00 End of session
  56. 56. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER54 14.30 – 16.00 INSTRUCTIONAL COURSE 25 Eye Brain: Retinal Nerve Fiber Layer (RNFL) Analysis in the Evaluation of Neurodegenerative Disorders Boulevard E (Level 1) Course Organisers: P. Barboni ITALY A. Grzybowski POLAND Cost: €25 14.30 A. Grzybowski POLAND Eye and brain – introduction 14.43 P. Barboni ITALY RGCs in neurodegenerative diseases 14.56 F. Cordeiro UK Retinal imaging animal models of neurodegenerative diseases 15.09 P. Yu Wai Man UK OCT and inherited optic neuropathies 15.22 J. Ascaso SPAIN OCT in schizophrenia 15.35 I. Bodis-Wallner USA OCT in Parkinson disease 15.48 Discussion 16.00 End of course 14.30 – 16.00 RETINAWS SYMPOSIUM Misadventures in the Operating Room Boulevard D (Level 1) Chairperson: K. Rezaei USA Panel: C. Claes BELGIUM J. García Arumí SPAIN H. Heimann GERMAY K. Kadonosono JAPAN G. Pertille ITALY S. Rizzo ITALY R. Tadayoni FRANCE J. van Meurs THE NETHERLANDS Programme Topics: • Intra-operative OCT • Vascular occlusion during vitrectomy • Melanoma and retinal detachment • Coloboma • Trauma related retinal detachment • 27G vitrectomy • Tough PVD • Macular hole and retinal detachment in high myopia • Severe trauma • Capillary hemangioma in Von Hippel Lindau disease • Anterior melanoma • Massive choroidal hemorrhage • ERM Peeling
  57. 57. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER 55 14.30 – 16.00 INSTRUCTIONAL COURSE 26 Chromovitrectomy: Novel Vital Dyes Illumination Systems for Vitreoretinal Surgery Boulevard H ( Level 1) Chairpersons: C.H. Meyer SWITZERLAND E.B. Rodrigues BRAZIL 14.30 B.V. Stanzel GERMANY From cell culture to surgery: impact of experimental studies for the development on novel dyes 14.45 P.B. Henrich SWITZERLAND Illumination and contrast: impact of light the light source on the contrast of vital dyes 15.00 R. Tadayoni FRANCE Benefit of chromovitrectomy visualization in tractional maculopathies 15.15 S. Rizzo ITALY Ala Purple: a novel dye in chromovitrectomy 15.30 E.B. Rodrigues BRAZIL Future perspective in chromovitrectomy 15.45 Discussion 16.00 End of course 14.30 – 16.00 INSTRUCTIONAL COURSE 27 Differential Diagnosis of Intraocular Tumours and Pseudo-tumours Boulevard G (Level 1) Course Organiser: L. Zografos SWITZERLAND Cost: €25 14.30 N. Bechrakis AUSTRIA Differential diagnosis of small pigmented choroidal tumours 14.43 L. Desjardins FRANCE Differential diagnosis of un-pigmented choroidal tumours 14.56 T. Kivelä FINLAND Differential diagnosis of choroidal tumours in opaque media 15.09 F. Munier SWITZERLAND Differential diagnosis of intraocular tumours in pediatric population 15.22 L. Zografos SWITZERLAND Differential diagnosis of peripheral chorioretinal tumours and pseudo-tumours 15.35 E. Midena ITALY Differential diagnosis of tumours and pseudo-tumours of the optic disk 15.48 Discussion 16.00 End of course
  58. 58. LONDON14th EURETINA Congress SATURDAY 13 SEPTEMBER56 16.00 – 18.00 MAIN SESSION 7 IMAGING Boulevard C (Level 1) Chairpersons: F. Holz GERMANY R. Tadayoni FRANCE 16.00 F. Delori USA Quantitative autofluorescence imaging 16.15 R. Tadayoni FRANCE Imaging for recent onset neovascular AMD 16.30 P. Stalmans BELGIUM Imaging and disease classification of the vitreomacular interface 16.45 F. Holz GERMANY Imaging intrinsic signals in dry AMD 17.00 W. Drexler AUSTRIA Choroidal OCT imaging 17.15 G. Staurenghi ITALY When should I use widefield imaging? 17.30 S. Wolf SWITZERLAND Fluorescence lifetime imaging  17.45 Discussion 18.00 End of Session 14.30 – 16.00 INSTRUCTIONAL COURSE 28 Pathology Could be the Key in Complicated Intraocular Inflammatory Diagnosis Boulevard I (Level 1) Course Organiser: J.C. Pastor SPAIN Cost: €25 14.30 J.C. Pastor SPAIN Indications and techniques for intraocular biopsies 14.48 J.C. López SPAIN Samples management. Samples processing. Molecular biology techniques. 15.06 A. Sala, E. Carreño, S. Pastor-Idoate SPAIN Case presentations and discussion 15.24 J.C. Pastor SPAIN Final remarks 15.42 Discussion 16.00 End of course

×